US20090105267A1 - Octahydro-pyrrolo[3,4-b]pyrrole n-oxides - Google Patents
Octahydro-pyrrolo[3,4-b]pyrrole n-oxides Download PDFInfo
- Publication number
- US20090105267A1 US20090105267A1 US12/208,604 US20860408A US2009105267A1 US 20090105267 A1 US20090105267 A1 US 20090105267A1 US 20860408 A US20860408 A US 20860408A US 2009105267 A1 US2009105267 A1 US 2009105267A1
- Authority
- US
- United States
- Prior art keywords
- compounds
- disorder
- pyrrole
- vol
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YETODIXQMRZKEG-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropyrrolo[2,3-c]pyrrole Chemical compound C1NCC2NCCC21 YETODIXQMRZKEG-UHFFFAOYSA-N 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 182
- 238000000034 method Methods 0.000 claims abstract description 51
- 239000000651 prodrug Substances 0.000 claims abstract description 30
- 229940002612 prodrug Drugs 0.000 claims abstract description 30
- 150000003839 salts Chemical class 0.000 claims abstract description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 46
- 102000005962 receptors Human genes 0.000 claims description 43
- 108020003175 receptors Proteins 0.000 claims description 43
- 208000035475 disorder Diseases 0.000 claims description 35
- 230000000694 effects Effects 0.000 claims description 21
- 201000000980 schizophrenia Diseases 0.000 claims description 21
- 230000006735 deficit Effects 0.000 claims description 18
- 230000007278 cognition impairment Effects 0.000 claims description 15
- 208000008589 Obesity Diseases 0.000 claims description 13
- 235000020824 obesity Nutrition 0.000 claims description 13
- 208000024827 Alzheimer disease Diseases 0.000 claims description 12
- 208000006673 asthma Diseases 0.000 claims description 12
- 230000008901 benefit Effects 0.000 claims description 12
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 11
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 11
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 11
- 201000010105 allergic rhinitis Diseases 0.000 claims description 11
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 11
- 208000010877 cognitive disease Diseases 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 230000001225 therapeutic effect Effects 0.000 claims description 11
- CFHOENGFTLPCDX-JTPXSGRQSA-N 2-[4-[4-[(3ar,5r,6ar)-5-methyl-5-oxido-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrol-5-ium-1-yl]phenyl]phenyl]pyridazin-3-one Chemical compound C([C@@H]1C[N@+](C[C@@H]11)([O-])C)CN1C(C=C1)=CC=C1C(C=C1)=CC=C1N1N=CC=CC1=O CFHOENGFTLPCDX-JTPXSGRQSA-N 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 10
- 201000003631 narcolepsy Diseases 0.000 claims description 9
- 208000019116 sleep disease Diseases 0.000 claims description 9
- CFHOENGFTLPCDX-SWGGMNADSA-N 2-[4-[4-[(3ar,5s,6ar)-5-methyl-5-oxido-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrol-5-ium-1-yl]phenyl]phenyl]pyridazin-3-one Chemical compound C([C@@H]1C[N@@+](C[C@@H]11)([O-])C)CN1C(C=C1)=CC=C1C(C=C1)=CC=C1N1N=CC=CC1=O CFHOENGFTLPCDX-SWGGMNADSA-N 0.000 claims description 8
- UUVXXKYGYGZMRS-JFLXGGRUSA-N 2-[5-[4-[(3ar,5s,6ar)-5-methyl-5-oxido-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrol-5-ium-1-yl]phenyl]pyridin-2-yl]pyridazin-3-one Chemical compound C([C@@H]1C[N@@+](C[C@@H]11)([O-])C)CN1C(C=C1)=CC=C1C(C=N1)=CC=C1N1N=CC=CC1=O UUVXXKYGYGZMRS-JFLXGGRUSA-N 0.000 claims description 7
- 206010013654 Drug abuse Diseases 0.000 claims description 7
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 230000013016 learning Effects 0.000 claims description 7
- 208000011117 substance-related disease Diseases 0.000 claims description 7
- UUVXXKYGYGZMRS-ZNFWPTJWSA-N 2-[5-[4-[(3ar,5r,6ar)-5-methyl-5-oxido-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrol-5-ium-1-yl]phenyl]pyridin-2-yl]pyridazin-3-one Chemical compound C([C@@H]1C[N@+](C[C@@H]11)([O-])C)CN1C(C=C1)=CC=C1C(C=N1)=CC=C1N1N=CC=CC1=O UUVXXKYGYGZMRS-ZNFWPTJWSA-N 0.000 claims description 6
- 208000020925 Bipolar disease Diseases 0.000 claims description 6
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims description 6
- 206010010904 Convulsion Diseases 0.000 claims description 6
- 206010012289 Dementia Diseases 0.000 claims description 6
- 208000027601 Inner ear disease Diseases 0.000 claims description 6
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims description 6
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims description 6
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 claims description 6
- 208000027530 Meniere disease Diseases 0.000 claims description 6
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 6
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 208000032140 Sleepiness Diseases 0.000 claims description 6
- 206010041349 Somnolence Diseases 0.000 claims description 6
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 6
- 208000016620 Tourette disease Diseases 0.000 claims description 6
- 208000012886 Vertigo Diseases 0.000 claims description 6
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 6
- 230000004075 alteration Effects 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 206010015037 epilepsy Diseases 0.000 claims description 6
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims description 6
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 6
- 230000036651 mood Effects 0.000 claims description 6
- 201000003152 motion sickness Diseases 0.000 claims description 6
- 208000004296 neuralgia Diseases 0.000 claims description 6
- 208000021722 neuropathic pain Diseases 0.000 claims description 6
- 201000001119 neuropathy Diseases 0.000 claims description 6
- 230000007823 neuropathy Effects 0.000 claims description 6
- 230000001575 pathological effect Effects 0.000 claims description 6
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 6
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 6
- 208000020016 psychiatric disease Diseases 0.000 claims description 6
- 230000037321 sleepiness Effects 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 claims description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
- 231100000889 vertigo Toxicity 0.000 claims description 6
- 208000027491 vestibular disease Diseases 0.000 claims description 6
- 201000009030 Carcinoma Diseases 0.000 claims description 5
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 5
- 208000019695 Migraine disease Diseases 0.000 claims description 5
- 208000007920 Neurogenic Inflammation Diseases 0.000 claims description 5
- 206010040070 Septic Shock Diseases 0.000 claims description 5
- 206010027599 migraine Diseases 0.000 claims description 5
- 230000036303 septic shock Effects 0.000 claims description 5
- 201000009961 allergic asthma Diseases 0.000 claims description 4
- 239000000203 mixture Substances 0.000 abstract description 102
- -1 octahydro-pyrrolo[3,4-b]pyrrole N-oxides Chemical class 0.000 abstract description 23
- 239000003446 ligand Substances 0.000 abstract description 15
- 230000008569 process Effects 0.000 abstract description 8
- 239000005557 antagonist Substances 0.000 abstract description 4
- 230000001668 ameliorated effect Effects 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 96
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 56
- 239000000243 solution Substances 0.000 description 50
- 239000003814 drug Substances 0.000 description 41
- 239000000047 product Substances 0.000 description 29
- 229940079593 drug Drugs 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 20
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 20
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 19
- 238000011160 research Methods 0.000 description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 230000002829 reductive effect Effects 0.000 description 18
- 210000004556 brain Anatomy 0.000 description 17
- 238000005160 1H NMR spectroscopy Methods 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 238000004587 chromatography analysis Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 230000003389 potentiating effect Effects 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 10
- 230000003542 behavioural effect Effects 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 235000019439 ethyl acetate Nutrition 0.000 description 9
- 229960001340 histamine Drugs 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 230000000144 pharmacologic effect Effects 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 210000003169 central nervous system Anatomy 0.000 description 8
- 239000003395 histamine H3 receptor antagonist Substances 0.000 description 8
- 239000002502 liposome Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- GNIRITULTPTAQW-KNQAVFIVSA-N 2-[4-[4-[(3ar,6ar)-5-methyl-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrol-1-yl]phenyl]phenyl]pyridazin-3-one Chemical compound C([C@@H]1CN(C[C@@H]11)C)CN1C(C=C1)=CC=C1C(C=C1)=CC=C1N1N=CC=CC1=O GNIRITULTPTAQW-KNQAVFIVSA-N 0.000 description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 7
- 238000012512 characterization method Methods 0.000 description 7
- 230000036470 plasma concentration Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 238000009739 binding Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 229940044551 receptor antagonist Drugs 0.000 description 6
- 239000002464 receptor antagonist Substances 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 5
- KPOIZYXUEYJTEU-RLKOQAIRSA-N C[N+]1(O)C[C@H]2CCN(C3=CC=C(C4=CC=C(N5N=CC=CC5=O)C=C4)C=C3)[C@H]2C1 Chemical compound C[N+]1(O)C[C@H]2CCN(C3=CC=C(C4=CC=C(N5N=CC=CC5=O)C=C4)C=C3)[C@H]2C1 KPOIZYXUEYJTEU-RLKOQAIRSA-N 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 239000007984 Tris EDTA buffer Substances 0.000 description 5
- KFHYZKCRXNRKRC-MRXNPFEDSA-N abt-239 Chemical compound C[C@@H]1CCCN1CCC1=CC2=CC(C=3C=CC(=CC=3)C#N)=CC=C2O1 KFHYZKCRXNRKRC-MRXNPFEDSA-N 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229910052681 coesite Inorganic materials 0.000 description 5
- 230000019771 cognition Effects 0.000 description 5
- 229910052906 cristobalite Inorganic materials 0.000 description 5
- 150000002148 esters Chemical group 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 229910052682 stishovite Inorganic materials 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 229910052905 tridymite Inorganic materials 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- 229940115480 Histamine H3 receptor antagonist Drugs 0.000 description 4
- 102000004384 Histamine H3 receptors Human genes 0.000 description 4
- 108090000981 Histamine H3 receptors Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- QKDDJDBFONZGBW-UHFFFAOYSA-N N-Cyclohexy-4-(imidazol-4-yl)-1-piperidinecarbothioamide Chemical compound C1CC(C=2NC=NC=2)CCN1C(=S)NC1CCCCC1 QKDDJDBFONZGBW-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 150000001408 amides Chemical group 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 229960004063 propylene glycol Drugs 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 4
- JQFMTRCQEFPEMJ-MFKMUULPSA-N (3ar,6ar)-1-(4-bromophenyl)-5-methyl-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrole Chemical compound C([C@@H]1CN(C[C@@H]11)C)CN1C1=CC=C(Br)C=C1 JQFMTRCQEFPEMJ-MFKMUULPSA-N 0.000 description 3
- SWJPEBQEEAHIGZ-UHFFFAOYSA-N 1,4-dibromobenzene Chemical compound BrC1=CC=C(Br)C=C1 SWJPEBQEEAHIGZ-UHFFFAOYSA-N 0.000 description 3
- HQJQYILBCQPYBI-UHFFFAOYSA-N 1-bromo-4-(4-bromophenyl)benzene Chemical group C1=CC(Br)=CC=C1C1=CC=C(Br)C=C1 HQJQYILBCQPYBI-UHFFFAOYSA-N 0.000 description 3
- YURZEZLCFZPUBP-UHFFFAOYSA-N 2-(5-bromopyridin-2-yl)pyridazin-3-one Chemical compound N1=CC(Br)=CC=C1N1C(=O)C=CC=N1 YURZEZLCFZPUBP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000000543 Histamine Receptors Human genes 0.000 description 3
- 108010002059 Histamine Receptors Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical group C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- ACQBHJXEAYTHCY-UHFFFAOYSA-N cyclopropyl-[4-[3-(1H-imidazol-5-yl)propoxy]phenyl]methanone Chemical compound C=1C=C(OCCCC=2NC=NC=2)C=CC=1C(=O)C1CC1 ACQBHJXEAYTHCY-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- NYGXZCRPVBPJTA-BDAKNGLRSA-N tert-butyl (3ar,6ar)-2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[2,3-c]pyrrole-5-carboxylate Chemical compound C1CN[C@H]2CN(C(=O)OC(C)(C)C)C[C@H]21 NYGXZCRPVBPJTA-BDAKNGLRSA-N 0.000 description 3
- OIKZNKIPPFFTKA-BDAKNGLRSA-N tert-butyl (3ar,6ar)-3,3a,4,5,6,6a-hexahydro-2h-pyrrolo[2,3-c]pyrrole-1-carboxylate Chemical compound C1NC[C@@H]2N(C(=O)OC(C)(C)C)CC[C@@H]21 OIKZNKIPPFFTKA-BDAKNGLRSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000011285 therapeutic regimen Methods 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- OWVUSBADKMTQRA-PBHICJAKSA-N (3ar,6ar)-5-methyl-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrole Chemical compound C([C@@H]1CN(C[C@@H]11)C)CN1C(C=C1)=CC=C1B1OC(C)(C)C(C)(C)O1 OWVUSBADKMTQRA-PBHICJAKSA-N 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- JNQBUKKIKSKWKI-UHFFFAOYSA-N 2-(6-bromopyridin-3-yl)pyridazin-3-one Chemical compound C1=NC(Br)=CC=C1N1C(=O)C=CC=N1 JNQBUKKIKSKWKI-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- DAZIEJQLKZIFNC-UYAOXDASSA-N 2-[5-[4-[(3ar,6as)-5-methyl-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrol-1-yl]phenyl]pyridin-2-yl]pyridazin-3-one Chemical compound C([C@@H]1CN(C[C@H]11)C)CN1C(C=C1)=CC=C1C(C=N1)=CC=C1N1N=CC=CC1=O DAZIEJQLKZIFNC-UYAOXDASSA-N 0.000 description 2
- RFEBVEWGRABHPU-MRVPVSSYSA-N 2-[[(1r)-1-phenylethyl]azaniumyl]acetate Chemical compound OC(=O)CN[C@H](C)C1=CC=CC=C1 RFEBVEWGRABHPU-MRVPVSSYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- SMCBBXSIVNHYKV-FYYSTUEKSA-N C(C1=CC=CC=C1)(=O)[C@@]([C@@](C(=O)O)(O)C(C1=CC=CC=C1)=O)(O)C(=O)O.C(C)OC(=O)N1C[C@H]2[C@@H](C1)CCN2 Chemical compound C(C1=CC=CC=C1)(=O)[C@@]([C@@](C(=O)O)(O)C(C1=CC=CC=C1)=O)(O)C(=O)O.C(C)OC(=O)N1C[C@H]2[C@@H](C1)CCN2 SMCBBXSIVNHYKV-FYYSTUEKSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- CFUHKRLMDNFZED-NHCUHLMSSA-N a-349,821 Chemical compound C[C@@H]1CC[C@@H](C)N1CCCOC1=CC=C(C=2C=CC(=CC=2)C(=O)N2CCOCC2)C=C1 CFUHKRLMDNFZED-NHCUHLMSSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- LXDJUCZFLBOTOY-IUDNXUCKSA-N ethyl 1-[(1r)-1-phenylethyl]-2,3,3a,4,6,6a-hexahydropyrrolo[3,4-b]pyrrole-5-carboxylate Chemical compound C1([C@@H](C)N2CCC3CN(CC32)C(=O)OCC)=CC=CC=C1 LXDJUCZFLBOTOY-IUDNXUCKSA-N 0.000 description 2
- SULDDMOQJXWUNO-UHFFFAOYSA-N ethyl 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[2,3-c]pyrrole-5-carboxylate Chemical compound C1CNC2CN(C(=O)OCC)CC21 SULDDMOQJXWUNO-UHFFFAOYSA-N 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 239000003885 eye ointment Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- 229940011051 isopropyl acetate Drugs 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 230000003137 locomotive effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003705 neurological process Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 239000002469 receptor inverse agonist Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000003206 sterilizing agent Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- FHAVIHRGFPFSRJ-DOMZBBRYSA-N tert-butyl (3ar,6ar)-1-(4-bromophenyl)-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrole-5-carboxylate Chemical compound C([C@@H]1CN(C[C@@H]11)C(=O)OC(C)(C)C)CN1C1=CC=C(Br)C=C1 FHAVIHRGFPFSRJ-DOMZBBRYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- KPXVCGPCRXEDLT-OAHLLOKOSA-N (2r)-2-amino-1-[4-[3-[4-(cyclopropanecarbonyl)phenoxy]propyl]piperazin-1-yl]propan-1-one Chemical compound C1CN(C(=O)[C@H](N)C)CCN1CCCOC1=CC=C(C(=O)C2CC2)C=C1 KPXVCGPCRXEDLT-OAHLLOKOSA-N 0.000 description 1
- CORVHUIUUFFPND-APWZRJJASA-N (3ar,6ar)-1-[4-(4-bromophenyl)phenyl]-5-methyl-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrole Chemical compound C([C@@H]1CN(C[C@@H]11)C)CN1C(C=C1)=CC=C1C1=CC=C(Br)C=C1 CORVHUIUUFFPND-APWZRJJASA-N 0.000 description 1
- DLUDAUJQMXTXGQ-RQJHMYQMSA-N (3ar,6ar)-5-methyl-2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[2,3-c]pyrrole Chemical compound C1CN[C@H]2CN(C)C[C@H]21 DLUDAUJQMXTXGQ-RQJHMYQMSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- NMFYOHITLSXXSK-CABCVRRESA-N 1-o-benzyl 5-o-ethyl (3ar,6ar)-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrole-1,5-dicarboxylate Chemical compound C([C@@H]1CN(C[C@@H]11)C(=O)OCC)CN1C(=O)OCC1=CC=CC=C1 NMFYOHITLSXXSK-CABCVRRESA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- ZHXUWDPHUQHFOV-UHFFFAOYSA-N 2,5-dibromopyridine Chemical compound BrC1=CC=C(Br)N=C1 ZHXUWDPHUQHFOV-UHFFFAOYSA-N 0.000 description 1
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 1
- OOMSNCHSZOWQJN-NQIIRXRSSA-N 2-[4-[4-[(3ar,6ar)-3,3a,4,5,6,6a-hexahydro-2h-pyrrolo[2,3-c]pyrrol-1-yl]phenyl]phenyl]pyridazin-3-one Chemical compound O=C1C=CC=NN1C1=CC=C(C=2C=CC(=CC=2)N2[C@H]3CNC[C@H]3CC2)C=C1 OOMSNCHSZOWQJN-NQIIRXRSSA-N 0.000 description 1
- DAZIEJQLKZIFNC-QUCCMNQESA-N 2-[5-[4-[(3ar,6ar)-5-methyl-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrol-1-yl]phenyl]pyridin-2-yl]pyridazin-3-one Chemical compound C([C@@H]1CN(C[C@@H]11)C)CN1C(C=C1)=CC=C1C(C=N1)=CC=C1N1N=CC=CC1=O DAZIEJQLKZIFNC-QUCCMNQESA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- NSUDGNLOXMLAEB-UHFFFAOYSA-N 5-(2-formyl-3-hydroxyphenoxy)pentanoic acid Chemical compound OC(=O)CCCCOC1=CC=CC(O)=C1C=O NSUDGNLOXMLAEB-UHFFFAOYSA-N 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 0 C*1C[C@](*(CC2)c(cc3)ccc3-c3ccc(*(*=CC=C4)C4=O)nc3)[C@@]2C1 Chemical compound C*1C[C@](*(CC2)c(cc3)ccc3-c3ccc(*(*=CC=C4)C4=O)nc3)[C@@]2C1 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 229910020889 NaBH3 Inorganic materials 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 241000862969 Stella Species 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 150000001930 cyclobutanes Chemical class 0.000 description 1
- 150000001934 cyclohexanes Chemical class 0.000 description 1
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- LCSNDSFWVKMJCT-UHFFFAOYSA-N dicyclohexyl-(2-phenylphenyl)phosphane Chemical group C1CCCCC1P(C=1C(=CC=CC=1)C=1C=CC=CC=1)C1CCCCC1 LCSNDSFWVKMJCT-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- WIWZWQOKDXAIIF-XLIONFOSSA-N ethyl (3ar,6ar)-1-[4-(4-bromophenyl)phenyl]-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrole-5-carboxylate Chemical compound C([C@@H]1CN(C[C@@H]11)C(=O)OCC)CN1C(C=C1)=CC=C1C1=CC=C(Br)C=C1 WIWZWQOKDXAIIF-XLIONFOSSA-N 0.000 description 1
- VSDXDUQCESSBQB-OFNKIYASSA-N ethyl (3ar,6ar)-1-[4-[4-(6-oxopyridazin-1-yl)phenyl]phenyl]-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrole-5-carboxylate Chemical compound C([C@@H]1CN(C[C@@H]11)C(=O)OCC)CN1C(C=C1)=CC=C1C(C=C1)=CC=C1N1N=CC=CC1=O VSDXDUQCESSBQB-OFNKIYASSA-N 0.000 description 1
- SULDDMOQJXWUNO-SFYZADRCSA-N ethyl (3ar,6ar)-2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[2,3-c]pyrrole-5-carboxylate Chemical compound C1CN[C@H]2CN(C(=O)OCC)C[C@H]21 SULDDMOQJXWUNO-SFYZADRCSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- IQQODTFRDRREIO-UHFFFAOYSA-N ethyl n-(2-oxoethyl)-n-prop-2-enylcarbamate Chemical compound CCOC(=O)N(CC=C)CC=O IQQODTFRDRREIO-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000010575 fractional recrystallization Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 230000000742 histaminergic effect Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- DMDBHLORZIDHQB-UHFFFAOYSA-N methyl 2-(1-phenylethylamino)acetate Chemical compound COC(=O)CNC(C)C1=CC=CC=C1 DMDBHLORZIDHQB-UHFFFAOYSA-N 0.000 description 1
- DMDBHLORZIDHQB-SECBINFHSA-N methyl 2-[[(1r)-1-phenylethyl]amino]acetate Chemical compound COC(=O)CN[C@H](C)C1=CC=CC=C1 DMDBHLORZIDHQB-SECBINFHSA-N 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- RTRADBQSZJIRMT-GOSISDBHSA-N n-[(2r)-1-[4-[3-[4-(cyclopropanecarbonyl)phenoxy]propyl]piperazin-1-yl]-1-oxopropan-2-yl]furan-2-carboxamide Chemical compound N([C@H](C)C(=O)N1CCN(CCCOC=2C=CC(=CC=2)C(=O)C2CC2)CC1)C(=O)C1=CC=CO1 RTRADBQSZJIRMT-GOSISDBHSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000036403 neuro physiology Effects 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000036278 prepulse Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- QAVYARXXRYFCCS-ZJUUUORDSA-N tert-butyl (3ar,6ar)-5-methyl-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrole-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)[C@H]2CN(C)C[C@H]21 QAVYARXXRYFCCS-ZJUUUORDSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Definitions
- the invention relates to octahydro-pyrrolo[3,4-b]pyrrole N-oxides, compositions comprising such compounds, methods for making the compounds, salts, and polymorphs, and methods of using said compounds as prodrugs for treating conditions and disorders where modulation of histamine-3 (H 3 ) receptor activity is of therapeutic benefit.
- Histamine is a well-known modulator of neuronal activity. At least four types of histamine receptors have been reported in the literature, typically referred to as histamine-1, histamine-2, histamine-3, and histamine-4.
- the class of histamine receptor known as the histamine-3 receptor (also sometimes called the histamine H 3 receptor or the H 3 receptor) is believed to play a role in neurotransmission in the central nervous system.
- the histamine-3 (H 3 ) receptor was first pharmacologically characterized on histaminergic nerve terminals (Arrang et al, “Auto-inhibition of Brain Histamine Release Mediated by a Novel Class (H 3 ) of Histamine Receptor”, Nature , Vol. 302, pp. 832-837 (1983)).
- the histamine-3 receptor is able to regulate the release of neurotransmitters in the central nervous system and peripheral nervous system, and also in peripheral organs such as the gastrointestinal tract. Histamine-3 ligands have been shown to be able to modulate the release of histamine, dopamine, serotonin, acetylcholine, and other neurotransmitters.
- histamine-3 receptors and their established role in modulating neurotransmitter release activity in animal models of disease indicate the utility of histamine-3 ligands for the treatment of disease. This has motivated a search for, and the development of, selective histamine-3 receptor agonists and antagonists (Leurs et al., Nature Reviews Drug Discovery , Vol. 4, pp. 107-120 (2005); Arrang et al. “Highly potent and selective ligands for histamine H3-receptors,” Nature , Vol. 327, pp. 117-123 (1987); Leurs and Timmerman, ed. “The History of H 3 Receptor: A Target for New Drugs,” Elsevier (1998)).
- histamine-3 receptors can be modified or regulated by the administration of histamine-3 receptor ligands.
- the ligands can demonstrate antagonist, inverse agonist, or partial agonist activity.
- Histamine-3 receptors have been linked to conditions and disorders related to the central nervous system involving memory, cognition, attention, and other neurological processes, wakefulness, obesity, and also peripheral and systemic activities, such as those involved in asthma and allergic rhinitis.
- various classes of compounds demonstrating histamine-3 receptor-modulating activity exist, it would be beneficial to provide additional compounds that can be incorporated into pharmaceutical compositions useful for therapeutic methods.
- Prodrugs are a suitable manner for providing therapeutic compounds. Approximately 5-7% of all commercial drugs worldwide are prodrugs (Stella, Expert Opinion on Therapeutic Patents , Vol. 14, pp. 277-280 (2004)). Prodrugs distinguish themselves in one or more significant ways. They are structurally different from the active daughter compound, and they may have distinct physicochemical properties. Prodrugs can therefore be used, for example, to solve drug delivery problems, and in general to overcome some barriers to the utility of the parent drug molecule, for example, they can help bypassing of drug efflux mechanisms, extend and delay drug absorption to extend the period of drug action, and generally improve bioavailability and biodistribution.
- the invention relates to octahydro-pyrrolo[3,4-b]pyrrole N-oxides as prodrugs of histamine-3 receptor ligands.
- the prodrugs of the invention can be useful to treat disorders where modulation of histamine-3 receptor activity is of therapeutic benefit.
- the invention is directed to octahydro-pyrrolo[3,4-b]pyrrole N-oxides having a compound of formula (I):
- compositions comprising compounds of the invention.
- Such compositions can be administered in accordance with a method of the invention, typically as part of a therapeutic regimen for treatment or prevention of conditions and disorders related to histamine-3 receptor activity.
- Another aspect of the invention relates to a method of treating a mammal having a condition where modulation of histamine-3 receptor activity is of therapeutic benefit, said method comprising administering to a subject having or susceptible to said disorder with a therapeutically effective amount of a compound of the formula (I).
- Another aspect of the invention is the use of a compound of formula (I)
- Z 2 is N or CH
- to treat a mammal having a condition or disorder where modulation of histamine-3 receptor activity is of therapeutic benefit comprising administering to a subject having or susceptible to said condition or disorder a therapeutically effective amount of a compound of the formula (I).
- Another aspect of the invention relates to a method for preparing compounds of formula (I).
- Another aspect of the invention relates to a method of using a compound of formula (I) to selectively modulate histamine-3 receptor activity.
- compounds of formula (II) are formed in animals.
- the compounds of formula (II) are potent histamine-3 receptor antagonists that are active and beneficial in animal models of central nervous system disease. The method is useful for treating, or preventing conditions and disorders related to histamine-3 receptor modulation in mammals.
- Such conditions and disorders include Alzheimer's disease, asthma, allergic rhinitis, attention-deficit hyperactivity disorder, deficits in attention, bipolar disorder, cognitive dysfunction, cognitive deficits in psychiatric disorders, deficits of memory, deficits of learning, dementia, cutaneous carcinoma, drug abuse, diabetes, type II diabetes, depression, epilepsy, gastrointestinal disorders, inflammation, insulin resistance syndrome, jet lag, medullary thyroid carcinoma, melanoma, Meniere's disease, vestibular disorders, metabolic syndrome, mild cognitive impairment, migraine, mood and attention alteration, motion sickness, narcolepsy, pathological sleepiness, neurogenic inflammation, obesity, obsessive compulsive disorder, pain, neuropathic pain, neuropathy, Parkinson's disease, polycystic ovary syndrome, schizophrenia, cognitive deficits of schizophrenia, seizures, septic shock, Syndrome X, Tourette's syndrome, vertigo, and sleep disorders.
- the method is useful for treating or preventing conditions and disorders related to the central nervous system involving memory, cognitive and other neurological processes, obesity, and also peripheral and systemic activities, such those involved in asthma, allergic rhinitis and obesity.
- the compounds and compositions of the invention are useful as a medicament for treating or preventing histamine-3 receptor modulated disease.
- the invention also relates to particular salts and polymorphs of certain compounds of the invention, as well as compositions comprising and processes for preparing such compounds, salts, and polymorphs.
- the invention also relates to compounds that are intermediates in processes for preparing the compounds, salts, and polymorphs described herein.
- compositions comprising the compounds, processes for making the compounds, methods for treating or preventing conditions and disorders by administering the compounds, radiolabelled forms of the compounds, particular salts of certain compounds, particularly polymorphs of certain compounds, and compositions containing such salts, polymorphs, and radiolabelled forms of the compounds are further described herein.
- Z 1 is N or CH.
- composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier.
- Preferred compounds of the invention are (3aR,5R,6aR)-5-methyl-1-(4′-(6-oxopyridazin-1(6H)-yl)biphenyl-4-yl)octahydropyrrolo[3,4-b]pyrrole 5-oxide, (3aR,5S,6aR)-5-methyl-1-(4′-(6-oxopyridazin-1(6H)-yl)biphenyl-4-yl)octahydropyrrolo[3,4-b]pyrrole 5-oxide, (3aR,5R,6aR)-5-methyl-1-(4-(6-(6-oxopyridazin-1(6H)-yl)pyridin-3-yl)phenyl)octahydropyrrolo[3,4-b]pyrrole 5-oxide, and (3aR,5S,6aR)-5-methyl-1-(4-(6-(6-o
- Stereoisomers may exist as stereoisomers wherein asymmetric or chiral centers are present. These stereoisomers are “R” or “S” depending on the configuration of substituents around the chiral carbon atom.
- R and S used herein are configurations as defined in IUPAC (International Union of Pure and Applied Chemistry) 1974 Recommendations, Section E: Fundamental Stereochemistry ( Pure & Appl. Chem ., Vol. 45, pp. 11-30, (1976)).
- Stereoisomers include enantiomers and diastereomers, and mixtures of enantiomers or diastereomers.
- Individual stereoisomers of compounds of the invention may be prepared synthetically from commercially available starting materials, which contain asymmetric or chiral centers, or by preparation of racemic mixtures followed by methods of resolution well-known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and optional liberation of the optically pure product from the auxiliary as described in Furniss, Hannaford, Smith, and Tatchell, “Vogel's Textbook of Practical Organic Chemistry”, 5th edition (1989); and Longman Scientific & Technical, Essex CM20 2JE, England, or (2) direct separation of the mixture of optical enantiomers on chiral chromatographic columns, or (3) fractional recrystallization methods.
- Compounds of the invention may exist as cis or trans isomers, wherein substituents on a ring may be attached in such a manner that they are on the same side of the ring (cis) relative to each other, or on opposite sides of the ring relative to each other (trans).
- substituents on a ring may be attached in such a manner that they are on the same side of the ring (cis) relative to each other, or on opposite sides of the ring relative to each other (trans).
- cyclobutanes and cyclohexanes may be present in the cis or trans configuration and may be present as a single isomer or a mixture of the cis and trans isomers.
- Individual cis or trans isomers of compounds of the invention may be prepared synthetically from commercially available starting materials using selective organic transformations, or prepared in single isomeric form by purification of mixtures of the cis and trans isomers. Such methods are well-known to those of ordinary skill in the art and may include separation of
- the compounds of the invention may possess tautomeric forms, as well as geometric isomers, and that these also constitute an aspect of the invention. It is also understood that the compounds of the invention may exist as isotopomers, wherein atoms may have different weights; for example, hydrogen, deuterium and tritium, or 12 C, 11 C and 13 C, or 19 F and 18 F.
- compounds and compositions of the invention of formula (I) are converted in vivo into compounds of formula (II), and therefore are useful as prodrugs of compounds of formula (II).
- compounds of formula (I) are not potent histamine-3 receptor antagonists or inverse agonists
- compounds of formula (II) are potent histamine-3 receptor antagonists and inverse agonists. Therefore compounds of formula (I) are useful for modulating the effects of histamine-3 receptors.
- the compounds and compositions of the invention can be used for treating and preventing disorders modulated by histamine-3 receptors.
- disorders can be ameliorated by modulating the histamine-3 receptors in a mammal, preferably by administering a compound or composition of the invention, either alone or in combination with another active agent, for example, as part of a therapeutic regimen.
- Such conditions or disorders can be selected from the group consisting of Alzheimer's disease, asthma, allergic rhinitis, attention-deficit hyperactivity disorder, deficits in attention, bipolar disorder, cognitive dysfunction, cognitive deficits in psychiatric disorders, deficits of memory, deficits of learning, dementia, cutaneous carcinoma, drug abuse, diabetes, type II diabetes, depression, epilepsy, gastrointestinal disorders, inflammation, insulin resistance syndrome, jet lag, medullary thyroid carcinoma, melanoma, Meniere's disease, vestibular disorders, metabolic syndrome, mild cognitive impairment, migraine, mood and attention alteration, motion sickness, narcolepsy, pathological sleepiness, neurogenic inflammation, obesity, obsessive compulsive disorder, pain, neuropathic pain, neuropathy, Parkinson's disease, polycy
- a mammal having attention-deficit hyperactivity disorder, Alzheimer's disease, or dementia can benefit from the administration of a therapeutically effective amount of a compound of formula (I).
- a mammal having schizophrenia or cognitive deficits of schizophrenia can benefit from the administration of a therapeutically effective amount of a compound of formula (I).
- a mammal having narcolepsy, sleep disorders, allergic rhinitis, asthma, or obesity can benefit from the administration of a therapeutically effective amount of a compound of formula (I).
- the compounds and compositions of formula (I) are useful for treating and preventing diseases, conditions and disorders modulated by histamine-3 receptors. Accordingly, the compounds or compositions of the invention can be administered either alone or in combination with another active agent as part of a therapeutic regimen.
- Preferred compounds of formula (I) useful for the methods disclosed herein are (3aR,5R,6aR)-5-methyl-1-(4′-(6-oxopyridazin-1(6H)-yl)biphenyl-4-yl)octahydropyrrolo[3,4-b]pyrrole 5-oxide, (3aR,5S,6aR)-5-methyl-1-(4′-(6-oxopyridazin-1(6H)-yl)biphenyl-4-yl)octahydropyrrolo[3,4-b]pyrrole 5-oxide, (3aR,5R,6aR)-5-methyl-1-(4-(6-(6-oxopyridazin-1(6H)-yl)pyridin-3-yl)phenyl)octa
- Such compounds may be useful for the treatment and prevention of diseases, conditions, or disorders related to histamine-3 modulation.
- diseases, conditions or disorders are, for example, Alzheimer's disease, asthma, allergic rhinitis, attention-deficit hyperactivity disorder, deficits in attention, bipolar disorder, cognitive dysfunction, cognitive deficits in psychiatric disorders, deficits of memory, deficits of learning, dementia, cutaneous carcinoma, drug abuse, diabetes, type II diabetes, depression, epilepsy, gastrointestinal disorders, inflammation, insulin resistance syndrome, jet lag, medullary thyroid carcinoma, melanoma, Meniere's disease, vestibular disorders, metabolic syndrome, mild cognitive impairment, migraine, mood and attention alteration, motion sickness, narcolepsy, pathological sleepiness, neurogenic inflammation, obesity, obsessive compulsive disorder, pain, neuropathic pain, neuropathy, Parkinson's disease, polycystic ovary syndrome, schizophrenia, cognitive deficits of schizophrenia, seizures, septic shock, Syndrome X, Tourette's syndrome, vertigo
- Amphetamine is an abused stimulant in humans. It, and similar abused drugs stimulate locomotor activity in animals, and it has been found that the histamine-3 antagonist thioperamide suppresses the locomotor stimulation induced by amphetamine. Therefore histamine-3 antagonists are likely to be useful for treating drug abuse as may be demonstrated by Clapham et al., European Journal of Pharmacology , Vol. 259 (2), pp. 107-14 (1994).
- Parkinson's disease a disease wherein patients have deficits in the ability to initiate movements, and patients' brains have low dopamine levels
- Parkinson's disease a disease wherein patients have deficits in the ability to initiate movements, and patients' brains have low dopamine levels
- Sánchez-Lemus et al. Neuroscience Letters , Vol. 364, pp. 179-184 (2004); Sakai et al., Life Sciences , Vol. 48, pp. 2397-2404 (1991); Fox et al., Journal of Pharmacology and Experimental Therapeutics , Vol. 313, pp. 176-190 (2005); Chen et al., British Journal of Pharmacology , Vol. 143, pp. 573-580 (2004).
- Compounds of the invention are particularly useful for treating and preventing a condition or disorder affecting attention-deficit hyperactivity, Alzheimer's disease, or dementia.
- Compounds of the invention are particularly useful for treating and preventing a condition or disorder affecting schizophrenia or cognitive deficits of schizophrenia.
- Compounds of the invention are particularly useful for treating and preventing a condition or disorder affecting narcolepsy, sleep disorders, allergic rhinitis, asthma, or obesity.
- Actual dosage levels of active ingredients in the pharmaceutical compositions of this invention can be varied so as to obtain an amount of the active compound(s) that is effective to achieve the desired therapeutic response for a particular patient, compositions and mode of administration.
- the selected dosage level will depend upon the activity of the particular compound, the route of administration, the severity of the condition being treated, and the condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.
- a therapeutically effective amount of one of the compounds of the invention can be employed in pure form, or where such forms exist, in pharmaceutically acceptable salt, ester, amide or prodrug form.
- the compound can be administered as a pharmaceutical composition containing the compound of interest in combination with one or more pharmaceutically acceptable carriers.
- therapeutically effective amount means a sufficient amount of the compound to treat disorders, at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the compounds and compositions of the invention will be decided by the attending physician within the scope of sound medical judgment.
- the specific therapeutically effective dosage level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well-known in the medical arts. For example, it is well within the skill of the art to start dosages of the compound at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.
- the total daily dosage of the compounds of this invention administered to a human or lower animal may range from about 0.0003 mg/kg to about 30 mg/kg of body weight.
- more preferable doses can be in the range of from about 0.001 mg/kg to about 0.1 mg/kg body weight.
- the effective daily dosage can be divided into multiple dosages for purposes of administration. Consequently, single dosage compositions may contain such amounts or submultiples thereof to make up the daily dosage.
- Xantphos for 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene, [161265-03-8]; BINAP for 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl; Boc for butyloxycarbonyl; EtOAc for ethyl acetate; HPLC for high pressure liquid chromatography; IPA for isopropyl alcohol; Me for methyl; MeOH for methanol; Ms for methanesulfonyl; Pd for palladium; tBu for tert-butyl; TEA for triethylamine; TFA for trifluoroacetic acid; THF for tetrahydrofuran; and Ts for para-toluenesulfonyl; dba for dibenzylidine acetone; DCM for dichloromethane,
- Emrys process vial is a microwave process vial (10 ml or 30 ml glass vial with sealed cap) from PersonalChemistry AB (Uppsala). All microwave irradiation experiments were carried out using the Emrys synthesizer from PersonalChemistry AB (Uppsala). All experiments were carried out in sealed microwave process vials utilizing the standard absorbance level (300 W maximum power). If not stated otherwise, reaction times under microwave conditions reflect total irradiation times counted from the beginning of the irradiation. As identifiers of compounds available from descriptions reported in the literature or available commercially, CAS numbers may be used. CAS numbers are identifier numbers assigned to compounds by Chemical Abstracts Service of the American Chemical Society, and are well-known to those of ordinary skill in the art.
- the compounds of this invention can be prepared by a variety of synthetic procedures. Specific procedures for the preparation of the compounds of formula (I) are given.
- the citric acid solution was diluted with 205 mL of isopropyl acetate, and the mixture was neutralized with a solution of 51.2 g K 2 CO 3 in 120 g water, and thoroughly shaken. The layers were separated, and the aqueous layer was extracted again with 102 mL of isopropyl acetate. The organic extracts were combined and distilled under reduced pressure to provide an oil which was then diluted with 125 mL of MeOH to provide 140 g (100% yield) of the title compound as a 30% by weight solution in MeOH.
- Example A3 5% palladium hydroxide on activated carbon (13.9 g, 50% w/w in water) was added to a pressure reactor.
- the product of Example A3 (as 506.8 g of a 25.9 wt % solution of ethyl 1-((R)-1-phenylethyl)hexahydropyrrolo[2,3-c]pyrrole-5(1H)-carboxylate (131.3 g) in MeOH was added, followed by a MeOH rinse (37 g).
- the mixture was heated to 50° C. under an atmosphere of hydrogen (40 psi) for 4 hours.
- the mixture was filtered through HYFLO Filter Aid (HYFLO is a registered trademark of Celite Products Company of Los Angeles, Calif.) and rinsed with 200 mL of MeOH to provide a solution containing 78.9 g of the title compound.
- HYFLO Filter Aid HYFLO is a registered trademark of Celite Products Company of Los Angeles,
- (3aR,6aR)-hexahydro-pyrrolo[3,4-b]pyrrole-1-carboxylic acid tert-butyl ester may be prepared as described in Schenke et al, “Preparation of 2,7-Diazabicyclo[3.3.0]octanes”, U.S. Pat. No. 5,071,999 (1991), which provides a racemate which may be resolved by chromatography on a chiral column or by fractional crystallization of diasteromeric salts, or as described in Basha et al., “Substituted Diazabicycloalkane Derivatives”, U.S. Patent Publication Number 2005/0101602 (2005).
- Example A6 To a solution of the product of Example A6 (20.8 g, 0.86 mole) in MeOH (450 ml) was added aqueous 3N HCl (300 ml). The mixture was stirred at room temperature overnight, then concentrated to dryness at 30° C. under vacuum. The residue was treated with aqueous 1N NaOH to obtain a pH of 9-10. The mixture was concentrated to dryness. The crude material was purified by chromatography (eluting with a mixture of 10% MeOH and 1% NH 4 OH in dichloromethane) to provide the title compound.
- Example A7 The product of Example A7 (2.30 g, 18.2 mmole), 1,4-dibromobenzene (5.16 g, 20.9 mmole), tris(dibenzylideneacetone)dipalladium (340 mg, 0.36 mmole), racemic-2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (460 mg, 0.73 mmole) and sodium tert-butoxide (2.63 g, 27.3 mmole) were dissolved in 20 ml of toluene and heated to 70° C. under N 2 for 16 hours. The mixture was cooled to room temperature, diluted with water and extracted with dichloromethane (5 ⁇ ).
- reaction were carried out under ambient conditions (ranging from 17-27° C.), under nitrogen.
- column chromatography means flash chromatography carried out using silica gel, a technique well-known to those of ordinary skill in the art of organic synthesis.
- Example 1A The product of Example 1A (4.54 g, 12.6 mmole), 3(2H)-pyridazinone (2.41 g, 25.2 mmole), copper powder (1.60 g, 25.2 mmole) and potassium carbonate (5.21 g, 37.7 mmole) were dissolved in 63 ml of quinoline and heated at 150° C. under N 2 for 48 hours. The mixture was cooled to room temperature, diluted with hexane (15 ml) and filtered through a CELITE filter (CELITE is a registered trademark of Johns-Manville Corporation of Denver, Colo.).
- CELITE filter CELITE is a registered trademark of Johns-Manville Corporation of Denver, Colo.
- Example A5 205 g
- CH 2 Cl 2 (1 L) a 20% KOH solution
- 1.54 L of a 20% KOH solution was cooled to 0° C. then slowly added to the salt slurry, and the biphasic reaction mixture was stirred vigorously at 0° C. After 2.75 hours, the layers were separated and the aqueous layer was extracted with CH 2 Cl 2 (1 L). The organic layers were combined and concentrated under reduced pressure, then chased with toluene (1.6 L) to provide 386 g of a 19 wt % solution of product (100%).
- the catalyst solution was added to the vessel containing the 4,4′-dibromobiphenyl, cesium carbonate, and the product of Example 41C and the mixture was heated to 98° C. for 12 hours.
- the mixture was cooled to 20° C. and 80 g of dichloromethane was added.
- the resulting mixture was stirred and then filtered to remove the catalyst.
- the resulting solution was concentrated under reduced pressure and the residue was purified by column chromatography to yield 5.65 g of the title compound.
- the mixture was added to another flask containing 41.6 g of the product of Example 1D (100.16 mmole, 1.00 eq.), 23.6 g of potassium carbonate (170.75 mmole, 1.70 eq.), and 14.4 g of 3(2H)-pyridazinone (149.86 mmole, 1.50 eq.). Additional DMF (226 g) was used to transfer the catalyst slurry. The resulting mixture was deoxygenated then heated to 140° C. for about 18 hours. After cooling to ambient temperature, the mixture was diluted with 567 g of THF and 384 g of 10% NaCl solution.
- Example 1E A mixture of the product of Example 1E (7.50 g, 17.42 mmol) in 33% HBr in acetic acid (37 mL, 205.57 mmol, 11.8 equivalents) was heated to 65-70° C. for at least 6 hours while monitored by HPLC analysis for completion. When reaction is complete, the mixture is cooled to not more than 45° C. and is diluted with MeOH (111 mL). The mixture was cooled to 20-25° C., the product is collected by filtration and is washed with fresh MeOH (50 mL). The wet cake is dried in the vacuum oven at not more than 55° C. to provide the title compound (7.25 g, 94.8%).
- Tert-butyl (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxylate may be prepared by the method described in Schrimpf et al., “Diazabicyclic Central Nervous System Active Agents”, WO 2001/081347(A2) (2001).
- 3-pyridazinone 300 mg, 3.1 mmol
- 2,5-dibromopyridine 1.0 g, 4.2 mmol
- copper powder 200 mg, 3.1 mmol
- K 2 CO 3 1.29 g, 9.3 mmol
- the mixture was heated to 120° C. in a microwave reactor for 40 minutes.
- the mixture was concentrated under reduced pressure after which the residue was taken up in CH 2 Cl 2 /MeOH, filtered and concentrated under reduced pressure.
- the crude mixture was purified via chromatography (SiO2, 10-80% EtOAc in hexanes) to provide the title compounds.
- the invention also provides pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula (I), or suitable salts and polymorphs thereof, in combination with a pharmaceutically acceptable carrier.
- the compositions comprise compounds of the invention formulated together with one or more non-toxic pharmaceutically acceptable carriers.
- the pharmaceutical compositions can be formulated for oral administration in solid or liquid form, for parenteral injection, or for rectal administration.
- pharmaceutically acceptable carrier means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
- materials which can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic
- compositions of this invention can be administered to humans and other mammals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments or drops), bucally or as an oral or nasal spray.
- parenterally refers to modes of administration, which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous, intraarticular injection and infusion.
- compositions for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
- suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol, and the like, and suitable mixtures thereof), vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate, or suitable mixtures thereof.
- Suitable fluidity of the composition may be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
- compositions may also contain adjuvants such as preservative agents, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example, sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form may be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.
- the absorption of the drug in order to prolong the effect of a drug, it is often desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
- Suspensions in addition to the active compounds, may contain suspending agents, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, tragacanth, and mixtures thereof.
- suspending agents for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, tragacanth, and mixtures thereof.
- the compounds of the invention can be incorporated into slow-release or targeted-delivery systems such as polymer matrices, liposomes, and microspheres. They may be sterilized, for example, by filtration through a bacteria-retaining filter or by incorporation of sterilizing agents in the form of sterile solid compositions, which may be dissolved in sterile water or some other sterile injectable medium
- Injectable depot forms are made by forming microencapsulated matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations also are prepared by entrapping the drug in liposomes or microemulsions, which are compatible with body tissues.
- the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.
- sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic, parenterally acceptable diluent or solvent such as a solution in 1,3-butanediol.
- acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil can be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid are used in the preparation of injectables.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
- one or more compounds of the invention is/are mixed with at least one inert pharmaceutically acceptable carrier, such as sodium citrate or dicalcium phosphate, and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and salicylic acid; b) binders such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia; c) humectants such as glycerol; d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; e) solution retarding agents such as paraffin; f) absorption accelerators such as quaternary ammonium compounds; g) wetting agents such as cetyl alcohol and glycerol monostea
- compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using lactose or milk sugar as well as high molecular weight polyethylene glycols.
- the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well-known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract in a delayed manner. Examples of materials which can be useful for delaying release of the active agent can include polymeric substances and waxes.
- compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
- suitable non-irritating carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and
- the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
- adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
- Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
- a desired compound of the invention is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
- Ophthalmic formulation, ear drops, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.
- the ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- Powders and sprays can contain, in addition to the compounds of this invention, lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.
- Compounds of the invention may also be administered in the form of liposomes.
- liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes may be used.
- compositions in liposome form may contain, in addition to the compounds of the invention, stabilizers, preservatives, and the like.
- the preferred lipids are the natural and synthetic phospholipids and phosphatidylcholines (lecithins) used separately or together.
- Dosage forms for topical administration of a compound of this invention include powders, sprays, ointments and inhalants.
- the active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers or propellants, which can be required.
- Opthalmic formulations, eye ointments, powders and solutions are contemplated as being within the scope of this invention.
- Aqueous liquid compositions comprising compounds of the invention also are contemplated.
- the compounds of the invention can be used in the form of pharmaceutically acceptable salts, esters, or amides derived from inorganic or organic acids.
- pharmaceutically acceptable salts, esters and amides refers to carboxylate salts, amino acid addition salts, zwitterions, esters and amides of compounds of formula (I) which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.
- pharmaceutically acceptable salt refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit/risk ratio.
- Pharmaceutically acceptable salts are well-known in the art. The salts can be prepared in situ during the final isolation and purification of the compounds of the invention or separately by reacting a free base function with a suitable organic acid or inorganic acid.
- Representative acid addition salts include, but are not limited to, ascorbic acid, (D)-tartaric acid, (L)-tartaric acid, phosphoric acid, salicylic acid, sulfuric acid, trifluoroacetic acid, and hydrochloric acid.
- the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates such as dimethyl, diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; arylalkyl halides such as benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained.
- lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides
- dialkyl sulfates such as dimethyl, diethyl, dibutyl and diamyl sulfates
- long chain halides such as de
- Basic addition salts can be prepared in situ during the final isolation and purification of compounds of this invention by reacting a carboxylic acid-containing moiety with a suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation or with ammonia or an organic primary, secondary or tertiary amine.
- a suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation or with ammonia or an organic primary, secondary or tertiary amine.
- Pharmaceutically acceptable salts include, but are not limited to, cations based on alkali metals or alkaline earth metals such as lithium, sodium, potassium, calcium, magnesium, and aluminum salts, and the like, and nontoxic quaternary ammonia and amine cations including ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, and the like.
- Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.
- the rat histamine-3 receptor was cloned and expressed in cells, and competition binding assays carried out, according to methods previously described (see Esbenshade et al., “Pharmacological Properties of ABT-239 [4-(2- ⁇ 2-[(2R)-2-Methylpyrrolidinyl]ethyl ⁇ -benzofuran-5-yl)benzonitrile]: I. Potent and Selective Histamine H3 Receptor Antagonist with Drug-Like Properties”, Journal of Pharmacology and Experimental Therapeutics , Vol. 313, pp.
- Membranes were prepared from C6 or HEK293 cells, expressing the rat histamine-3 receptor, by homogenization on ice in TE buffer (50 mM Tris-HCl buffer, pH 7.4, containing 5 mM EDTA), 1 mM benzamidine, 2 ⁇ g/ml aprotinin, 1 ⁇ g/ml leupeptin, and 1 ⁇ g/ml pepstatin. The homogenate was centrifuged at 40,000 g for 20 minutes at 4° C. This step was repeated, and the resulting pellet was resuspended in TE buffer. Aliquots were frozen at ⁇ 70° C. until needed. On the day of assay, membranes were thawed and diluted with TE buffer.
- Membrane preparations were incubated with [H 3 ]-N- ⁇ -methylhistamine (0.5-1.0 nM) in the presence or absence of increasing concentrations of ligands of formula (I) and formula (II) for histamine-3 receptor competition binding.
- the binding incubations were conducted in a final volume of 0.5 ml TE buffer at 25° C. and were terminated after 30 minutes.
- Thioperamide (30 ⁇ M) was used to define non-specific binding. All binding reactions were terminated by filtration under vacuum onto polyethylenimine (0.3%) presoaked PERKINELMER UniFilter plates (PERKINELMER is a registered trademark of PerkinElmer, Inc.
- the compounds of formula (I) are converted, after oral administration or in vivo administration to the compounds of formula (II).
- Compounds of formula (II) were tested as indicated above for histamine-3 receptor competition binding. As shown in Table 2, compounds of formula (II) have low K i values. This indicates that compounds of formula (II) are extremely potent as histamine-3 receptors.
- the prodrug was prepared as a solution in a vehicle of 20% EtOH: 30% propylene glycol in D5W (dextrose 5% in water) at concentrations ranging from 0.1-2 mg/ml.
- Groups of three rats, dogs or monkeys received a 1 mg/kg (0.5-1 ml/kg) intravenous or oral dose of the example prodrug; additional groups of 30 mice received a 1 mg/kg (10 ml/kg) intravenous or oral dose of the prodrug.
- the intravenous dose was administered in a jugular (rat), cephalic (dog) or saphenous (monkey) vein; the oral dose was administered by gavage.
- Serial blood samples were obtained from each animal 0.1 (IV only), 0.25, 0.5, 1, 1.5, 2, 4, 6, 9, 12, 15 (dog only) and 24 hours after dosing. Plasma was separated by centrifugation and stored frozen until analysis.
- the plasma concentrations of the administered prodrug and the corresponding histamine-3 receptor ligand were determined by HPLC-MS/MS.
- the compounds of interest were removed from the plasma using protein precipitation with acetonitrile. Following centrifugation, the supernatant was transferred to a clean container and evaporated to dryness with nitrogen.
- the prodrug and parent compound were separated from co-extracted contaminant using reverse phase HPLC, with MS/MS detection and quantitation. Spiked standards were analyzed simultaneously with the samples.
- the plasma drug concentration of each sample was calculated by least squares linear regression analysis (non-weighted) of the peak area ratio (prodrug or parent/internal standard) of the spiked plasma standards versus concentration.
- Peak plasma concentrations (C max ) and the time to peak plasma concentration (T max ) for both the administered prodrug and the parent drug were read directly from the plasma concentration data for each rat.
- the plasma concentration data were submitted to multi-exponential curve fitting using WINNONLIN Professional Version 4.0 software (WINNONLIN is a registered trademark of Pharsight Corporation of Palo Alto, Calif.).
- the characterized prodrug converted to a histamine-3 receptor ligand in all studies.
- the conversion from the prodrug was measured: complete conversion of the prodrug was observed in the monkey (no prodrug detected); about 50% conversion was noted in rat (prodrug: parent ratio ⁇ 1:1) and ⁇ 30% conversion in mouse (prodrug: parent ratio ⁇ 2:1); conversion was observed in dog (prodrug: parent ratio ⁇ 10:1), but less than in monkey, rat, and mouse.
Abstract
Description
- This application claims priority to U.S. Application No. 60/971,402, filed on Sep. 11, 2007, the contents of which are herein incorporated by reference.
- 1. Technical Field
- The invention relates to octahydro-pyrrolo[3,4-b]pyrrole N-oxides, compositions comprising such compounds, methods for making the compounds, salts, and polymorphs, and methods of using said compounds as prodrugs for treating conditions and disorders where modulation of histamine-3 (H3) receptor activity is of therapeutic benefit.
- 2. Description of Related Technology
- Histamine is a well-known modulator of neuronal activity. At least four types of histamine receptors have been reported in the literature, typically referred to as histamine-1, histamine-2, histamine-3, and histamine-4. The class of histamine receptor known as the histamine-3 receptor (also sometimes called the histamine H3 receptor or the H3 receptor) is believed to play a role in neurotransmission in the central nervous system.
- The histamine-3 (H3) receptor was first pharmacologically characterized on histaminergic nerve terminals (Arrang et al, “Auto-inhibition of Brain Histamine Release Mediated by a Novel Class (H3) of Histamine Receptor”, Nature, Vol. 302, pp. 832-837 (1983)). The histamine-3 receptor is able to regulate the release of neurotransmitters in the central nervous system and peripheral nervous system, and also in peripheral organs such as the gastrointestinal tract. Histamine-3 ligands have been shown to be able to modulate the release of histamine, dopamine, serotonin, acetylcholine, and other neurotransmitters. The existence of histamine-3 receptors and their established role in modulating neurotransmitter release activity in animal models of disease indicate the utility of histamine-3 ligands for the treatment of disease. This has motivated a search for, and the development of, selective histamine-3 receptor agonists and antagonists (Leurs et al., Nature Reviews Drug Discovery, Vol. 4, pp. 107-120 (2005); Arrang et al. “Highly potent and selective ligands for histamine H3-receptors,” Nature, Vol. 327, pp. 117-123 (1987); Leurs and Timmerman, ed. “The History of H3 Receptor: A Target for New Drugs,” Elsevier (1998)).
- The activity of histamine-3 receptors can be modified or regulated by the administration of histamine-3 receptor ligands. The ligands can demonstrate antagonist, inverse agonist, or partial agonist activity. Histamine-3 receptors have been linked to conditions and disorders related to the central nervous system involving memory, cognition, attention, and other neurological processes, wakefulness, obesity, and also peripheral and systemic activities, such as those involved in asthma and allergic rhinitis. Although various classes of compounds demonstrating histamine-3 receptor-modulating activity exist, it would be beneficial to provide additional compounds that can be incorporated into pharmaceutical compositions useful for therapeutic methods.
- Prodrugs are a suitable manner for providing therapeutic compounds. Approximately 5-7% of all commercial drugs worldwide are prodrugs (Stella, Expert Opinion on Therapeutic Patents, Vol. 14, pp. 277-280 (2004)). Prodrugs distinguish themselves in one or more significant ways. They are structurally different from the active daughter compound, and they may have distinct physicochemical properties. Prodrugs can therefore be used, for example, to solve drug delivery problems, and in general to overcome some barriers to the utility of the parent drug molecule, for example, they can help bypassing of drug efflux mechanisms, extend and delay drug absorption to extend the period of drug action, and generally improve bioavailability and biodistribution.
- The invention relates to octahydro-pyrrolo[3,4-b]pyrrole N-oxides as prodrugs of histamine-3 receptor ligands. As such, the prodrugs of the invention can be useful to treat disorders where modulation of histamine-3 receptor activity is of therapeutic benefit.
- The invention is directed to octahydro-pyrrolo[3,4-b]pyrrole N-oxides having a compound of formula (I):
- or a pharmaceutically acceptable salt, or polymorph thereof, wherein Z1 is N or CH.
- Another aspect of the invention relates to pharmaceutical compositions comprising compounds of the invention. Such compositions can be administered in accordance with a method of the invention, typically as part of a therapeutic regimen for treatment or prevention of conditions and disorders related to histamine-3 receptor activity.
- Another aspect of the invention relates to a method of treating a mammal having a condition where modulation of histamine-3 receptor activity is of therapeutic benefit, said method comprising administering to a subject having or susceptible to said disorder with a therapeutically effective amount of a compound of the formula (I).
- Another aspect of the invention is the use of a compound of formula (I)
- or a pharmaceutically acceptable salt, or polymorph thereof, as a prodrug of compounds of formula (II):
- wherein Z2 is N or CH, to treat a mammal having a condition or disorder where modulation of histamine-3 receptor activity is of therapeutic benefit, comprising administering to a subject having or susceptible to said condition or disorder a therapeutically effective amount of a compound of the formula (I).
- Another aspect of the invention relates to a method for preparing compounds of formula (I).
- Another aspect of the invention relates to a method of using a compound of formula (I) to selectively modulate histamine-3 receptor activity.
- After oral administration or in vivo administration of compounds of formula (I), compounds of formula (II) are formed in animals. The compounds of formula (II) are potent histamine-3 receptor antagonists that are active and beneficial in animal models of central nervous system disease. The method is useful for treating, or preventing conditions and disorders related to histamine-3 receptor modulation in mammals. Such conditions and disorders include Alzheimer's disease, asthma, allergic rhinitis, attention-deficit hyperactivity disorder, deficits in attention, bipolar disorder, cognitive dysfunction, cognitive deficits in psychiatric disorders, deficits of memory, deficits of learning, dementia, cutaneous carcinoma, drug abuse, diabetes, type II diabetes, depression, epilepsy, gastrointestinal disorders, inflammation, insulin resistance syndrome, jet lag, medullary thyroid carcinoma, melanoma, Meniere's disease, vestibular disorders, metabolic syndrome, mild cognitive impairment, migraine, mood and attention alteration, motion sickness, narcolepsy, pathological sleepiness, neurogenic inflammation, obesity, obsessive compulsive disorder, pain, neuropathic pain, neuropathy, Parkinson's disease, polycystic ovary syndrome, schizophrenia, cognitive deficits of schizophrenia, seizures, septic shock, Syndrome X, Tourette's syndrome, vertigo, and sleep disorders. More particularly, the method is useful for treating or preventing conditions and disorders related to the central nervous system involving memory, cognitive and other neurological processes, obesity, and also peripheral and systemic activities, such those involved in asthma, allergic rhinitis and obesity. Accordingly, the compounds and compositions of the invention are useful as a medicament for treating or preventing histamine-3 receptor modulated disease.
- The invention also relates to particular salts and polymorphs of certain compounds of the invention, as well as compositions comprising and processes for preparing such compounds, salts, and polymorphs. The invention also relates to compounds that are intermediates in processes for preparing the compounds, salts, and polymorphs described herein.
- The compounds, compositions comprising the compounds, processes for making the compounds, methods for treating or preventing conditions and disorders by administering the compounds, radiolabelled forms of the compounds, particular salts of certain compounds, particularly polymorphs of certain compounds, and compositions containing such salts, polymorphs, and radiolabelled forms of the compounds are further described herein.
- Compounds of the invention can have the formula (I) as described in the Summary of the Invention:
- wherein Z1 is N or CH.
- There is also disclosed a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier.
- Preferred compounds of the invention are (3aR,5R,6aR)-5-methyl-1-(4′-(6-oxopyridazin-1(6H)-yl)biphenyl-4-yl)octahydropyrrolo[3,4-b]pyrrole 5-oxide, (3aR,5S,6aR)-5-methyl-1-(4′-(6-oxopyridazin-1(6H)-yl)biphenyl-4-yl)octahydropyrrolo[3,4-b]pyrrole 5-oxide, (3aR,5R,6aR)-5-methyl-1-(4-(6-(6-oxopyridazin-1(6H)-yl)pyridin-3-yl)phenyl)octahydropyrrolo[3,4-b]pyrrole 5-oxide, and (3aR,5S,6aR)-5-methyl-1-(4-(6-(6-oxopyridazin-1(6H)-yl)pyridin-3-yl)phenyl)octahydropyrrolo[3,4-b]pyrrole 5-oxide.
- More preferred are (3aR,5R,6aR)-5-methyl-1-(4′-(6-oxopyridazin-1(6H)-yl)biphenyl-4-yl)octahydropyrrolo[3,4-b]pyrrole 5-oxide, and (3aR,5S,6aR)-5-methyl-1-(4′-(6-oxopyridazin-1(6H)-yl)biphenyl-4-yl)octahydropyrrolo[3,4-b]pyrrole 5-oxide.
- Most preferred is (3aR,5R,6aR)-5-methyl-1-(4′-(6-oxopyridazin-1(6H)-yl)biphenyl-4-yl)octahydropyrrolo[3,4-b]pyrrole 5-oxide.
- Compounds of the invention were named by ACD/ChemSketch version 5.01 (developed by Advanced Chemistry Development Inc., Toronto, Ontario, Canada), or CHEMDRAW Ultra 9.0 software (CHEMDRAW is a registered trademark of CambridgeSoft Corporation of Cambridge, Mass.), or were given names consistent with ACD (Advanced Chemistry Development) nomenclature. The practice of assigning names to chemical compounds from structures and of assigning chemical structures from given chemical names is well-known to those of ordinary skill in the art.
- Compounds of the invention may exist as stereoisomers wherein asymmetric or chiral centers are present. These stereoisomers are “R” or “S” depending on the configuration of substituents around the chiral carbon atom. The terms “R” and “S” used herein are configurations as defined in IUPAC (International Union of Pure and Applied Chemistry) 1974 Recommendations, Section E: Fundamental Stereochemistry (Pure & Appl. Chem., Vol. 45, pp. 11-30, (1976)). The invention contemplates various stereoisomers and mixtures thereof, and these are specifically included within the scope of this invention. Stereoisomers include enantiomers and diastereomers, and mixtures of enantiomers or diastereomers. Individual stereoisomers of compounds of the invention may be prepared synthetically from commercially available starting materials, which contain asymmetric or chiral centers, or by preparation of racemic mixtures followed by methods of resolution well-known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and optional liberation of the optically pure product from the auxiliary as described in Furniss, Hannaford, Smith, and Tatchell, “Vogel's Textbook of Practical Organic Chemistry”, 5th edition (1989); and Longman Scientific & Technical, Essex CM20 2JE, England, or (2) direct separation of the mixture of optical enantiomers on chiral chromatographic columns, or (3) fractional recrystallization methods.
- Compounds of the invention may exist as cis or trans isomers, wherein substituents on a ring may be attached in such a manner that they are on the same side of the ring (cis) relative to each other, or on opposite sides of the ring relative to each other (trans). For example, cyclobutanes and cyclohexanes may be present in the cis or trans configuration and may be present as a single isomer or a mixture of the cis and trans isomers. Individual cis or trans isomers of compounds of the invention may be prepared synthetically from commercially available starting materials using selective organic transformations, or prepared in single isomeric form by purification of mixtures of the cis and trans isomers. Such methods are well-known to those of ordinary skill in the art and may include separation of isomers by recrystallization or chromatography.
- It should be understood that the compounds of the invention may possess tautomeric forms, as well as geometric isomers, and that these also constitute an aspect of the invention. It is also understood that the compounds of the invention may exist as isotopomers, wherein atoms may have different weights; for example, hydrogen, deuterium and tritium, or 12C, 11C and 13C, or 19F and 18F.
- Compounds and compositions of the invention of formula (I) are converted in vivo into compounds of formula (II), and therefore are useful as prodrugs of compounds of formula (II). Although compounds of formula (I) are not potent histamine-3 receptor antagonists or inverse agonists, compounds of formula (II) are potent histamine-3 receptor antagonists and inverse agonists. Therefore compounds of formula (I) are useful for modulating the effects of histamine-3 receptors. In particular, the compounds and compositions of the invention can be used for treating and preventing disorders modulated by histamine-3 receptors. Typically, such disorders can be ameliorated by modulating the histamine-3 receptors in a mammal, preferably by administering a compound or composition of the invention, either alone or in combination with another active agent, for example, as part of a therapeutic regimen. Such conditions or disorders can be selected from the group consisting of Alzheimer's disease, asthma, allergic rhinitis, attention-deficit hyperactivity disorder, deficits in attention, bipolar disorder, cognitive dysfunction, cognitive deficits in psychiatric disorders, deficits of memory, deficits of learning, dementia, cutaneous carcinoma, drug abuse, diabetes, type II diabetes, depression, epilepsy, gastrointestinal disorders, inflammation, insulin resistance syndrome, jet lag, medullary thyroid carcinoma, melanoma, Meniere's disease, vestibular disorders, metabolic syndrome, mild cognitive impairment, migraine, mood and attention alteration, motion sickness, narcolepsy, pathological sleepiness, neurogenic inflammation, obesity, obsessive compulsive disorder, pain, neuropathic pain, neuropathy, Parkinson's disease, polycystic ovary syndrome, schizophrenia, cognitive deficits of schizophrenia, seizures, septic shock, Syndrome X, Tourette's syndrome, vertigo, and sleep disorders.
- In particular, a mammal having attention-deficit hyperactivity disorder, Alzheimer's disease, or dementia can benefit from the administration of a therapeutically effective amount of a compound of formula (I).
- In particular, a mammal having schizophrenia or cognitive deficits of schizophrenia can benefit from the administration of a therapeutically effective amount of a compound of formula (I).
- Additionally, a mammal having narcolepsy, sleep disorders, allergic rhinitis, asthma, or obesity can benefit from the administration of a therapeutically effective amount of a compound of formula (I).
- As an important consequence of the ability of the compounds of the invention to generate compounds of formula (II) that modulate the effects of histamine-3 receptors in animals, the compounds and compositions of formula (I) are useful for treating and preventing diseases, conditions and disorders modulated by histamine-3 receptors. Accordingly, the compounds or compositions of the invention can be administered either alone or in combination with another active agent as part of a therapeutic regimen.
- Compounds useful for the method of the invention, include but are not limited to, those specified in the Examples, and possess an affinity for the histamine-3 receptors. Preferred compounds of formula (I) useful for the methods disclosed herein are (3aR,5R,6aR)-5-methyl-1-(4′-(6-oxopyridazin-1(6H)-yl)biphenyl-4-yl)octahydropyrrolo[3,4-b]pyrrole 5-oxide, (3aR,5S,6aR)-5-methyl-1-(4′-(6-oxopyridazin-1(6H)-yl)biphenyl-4-yl)octahydropyrrolo[3,4-b]pyrrole 5-oxide, (3aR,5R,6aR)-5-methyl-1-(4-(6-(6-oxopyridazin-1(6H)-yl)pyridin-3-yl)phenyl)octahydropyrrolo[3,4-b]pyrrole 5-oxide, and (3aR,5S,6aR)-5-methyl-1-(4-(6-(6-oxopyridazin-1(6H)-yl)pyridin-3-yl)phenyl)octahydropyrrolo[3,4-b]pyrrole 5-oxide. More preferred are (3aR,5R,6aR)-5-methyl-1-(4′-(6-oxopyridazin-1(6H)-yl)biphenyl-4-yl)octahydropyrrolo[3,4-b]pyrrole 5-oxide, and (3aR,5S,6aR)-5-methyl-1-(4′-(6-oxopyridazin-1(6H)-yl)biphenyl-4-yl)octahydropyrrolo[3,4-b]pyrrole 5-oxide. Most preferred is (3aR,5R,6aR)-5-methyl-1-(4′-(6-oxopyridazin-1(6H)-yl)biphenyl-4-yl)octahydropyrrolo[3,4-b]pyrrole 5-oxide.
- Such compounds may be useful for the treatment and prevention of diseases, conditions, or disorders related to histamine-3 modulation. Examples of such diseases, conditions or disorders are, for example, Alzheimer's disease, asthma, allergic rhinitis, attention-deficit hyperactivity disorder, deficits in attention, bipolar disorder, cognitive dysfunction, cognitive deficits in psychiatric disorders, deficits of memory, deficits of learning, dementia, cutaneous carcinoma, drug abuse, diabetes, type II diabetes, depression, epilepsy, gastrointestinal disorders, inflammation, insulin resistance syndrome, jet lag, medullary thyroid carcinoma, melanoma, Meniere's disease, vestibular disorders, metabolic syndrome, mild cognitive impairment, migraine, mood and attention alteration, motion sickness, narcolepsy, pathological sleepiness, neurogenic inflammation, obesity, obsessive compulsive disorder, pain, neuropathic pain, neuropathy, Parkinson's disease, polycystic ovary syndrome, schizophrenia, cognitive deficits of schizophrenia, seizures, septic shock, Syndrome X, Tourette's syndrome, vertigo, and sleep disorders. The ability of histamine-3 receptor modulators and consequently, the compounds of the invention, to prevent or treat such diseases, conditions, or disorders is demonstrated by examples found in the following references.
- The ability of the compounds of the invention, including but not limited to, those specified in the Examples, to treat attention-deficit hyperactivity disorder and deficits in attention, may be demonstrated by Cowart et al., Journal of Medicinal Chemistry, Vol. 48, pp. 38-55 (2005); Fox et al., “Pharmacological Properties of ABT-239: II. Neurophysiological Characterization and Broad Preclinical Efficacy in Cognition and Schizophrenia of a Potent and Selective Histamine H3 Receptor Antagonist”, Journal of Pharmacology and Experimental Therapeutics, Vol. 313, pp. 176-190 (2005); Fox et al., “Effects of Histamine H3 Receptor Ligands GT-2331 and Ciproxifan in a Repeated Acquisition Avoidance Response in the Spontaneously Hypertensive Rat Pup”, Behavioural Brain Research, Vol. 131(1,2), pp. 151-161 (2002); Yates et al., “Identification and Pharmacological Characterization of a Series of New 1H-4-Substituted-Imidazoyl Histamine H3 Receptor Ligands”, Journal of Pharmacology and Experimental Therapeutics, Vol. 289, pp. 1151-1159 (1999); Ligneau et al., Journal of Pharmacology and Experimental Therapeutics, Vol. 287, pp. 658-666 (1998); Tozer, Expert Opinion on Therapeutic Patents, Vol. 10, p. 1045 (2000); Halpern, “GT-2331”, Current Opinion in Central and Peripheral Nervous System Investigational Drugs, Vol. 1, pp. 524-527 (1999); Shaywitz et al., Psychopharmacology, Vol. 82, pp. 73-77 (1984); Dumery et al., “Development of Amygdaloid Cholinergic Mediation of Passive Avoidance Learning in the Rat,” Exp. Brain Res., Vol. 67 pp. 61-69 (1987); Tedford et al., “Pharmacological Characterization of GT-2016, A Non-Thiourea-Containing Histamine H3 Receptor Antagonist: In Vitro and In Vivo Studies”, Journal of Pharmacology and Experimental Therapeutics, Vol. 275, pp. 598-604 (1995); Tedford et al., “Abstracts”, Society for Neuroscience, Vol. 22, p. 22 (1996); Glase et al., “Attention Deficit Hyperactivity Disorder: Pathophysiology and Design of New Treatments”, Annual Reports in Medicinal Chemistry, Vol. 37, pp. 11-20 (2002); Schweitzer et al., “Drugs Under Investigation for Attention-Deficit Hyperactivity Disorder”, Current Opinion in Investigative Drugs, Vol. 3, p. 1207 (2002).
- The ability of the compounds of the invention, including but not limited to, those specified in the Examples, to treat dementia, and diseases with deficits of memory and learning, may be demonstrated by Fox et al., Journal of Pharmacology and Experimental Therapeutics, Vol. 305(3), pp. 897-908 (2003); Fox; Inflammation Research, Vol. 52 (Suppl. 1), pp. S31-S32 (2003); Bernaerts et al., Behavioural Brain Research, Vol. 154 pp. 211-219 (2004); Onodera et al., Nauyn-Schmiedebergs' Arch. Pharmacol., Vol. 357, pp. 508-513 (1998); Prast et al., Brain Research, Vol. 734, pp. 316-318 (1996); Chen et al., Brain Research, Vol. 839, pp. 186-189 (1999); Passani et al., Neuroscience and Biobehavioral Reviews, Vol. 24, pp. 107-113 (2000).
- The ability of the compounds of the invention, including but not limited to, those specified in the Examples, to treat schizophrenia, cognitive deficits of schizophrenia, and cognitive deficits, may be demonstrated by Fox et al., “Pharmacological Properties of ABT-239: II. Neurophysiological Characterization and Broad Preclinical Efficacy in Cognition and Schizophrenia of a Potent and Selective Histamine H3 Receptor Antagonist”, Journal of Pharmacology and Experimental Therapeutics, Vol. 313, pp. 176-190 (2005); Browman et al., “Enhancement of Prepulse Inhibitor of Startle in Mice by the H3 Receptor Antagonists Thioperamide and Ciproxifan”, Behavioural Brain Research, Vol. 153(1), pp. 69-76 (2004); Komater et al., “H3 Receptor Blockade by Thioperamide Enhances Cognition Without Inducing Locomotor Sensitization”, Psychopharmacology (Berlin, Germany), Vol. 167(4), pp. 363-372 (2003); Rodrigues et al., British Journal of Pharmacology, Vol. 114(8), pp. 1523-1524 (1995); Passani et al., Neuroscience and Biobehavioral Reviews, Vol. 24, pp. 107-113 (2000); Morriset et al., Journal of Pharmacology and Experimental Therapeutics, Vol. 288, pp. 590-596 (1999).
- The ability of the compounds of the invention, including but not limited to, those specified in the Examples, to treat dysfunction in psychiatric disorders, Alzheimer's disease, and mild cognitive impairment may be demonstrated by Meguro et al., Pharmacology, Biochemistry and Behavior, Vol. 50(3), pp. 321-325 (1995); Esbenshade et al., “Pharmacological and Behavioral Properties of A-349821, a Selective and Potent Human Histamine H3 Receptor Antagonist”, Biochemical Pharmacology, Vol. 68, pp. 933-945 (2004); Huang et al., Behavioural Brain Research, Vol. 151, pp. 287-293 (2004); Mazurkiewicz-Kwilecki et al., Canadian Journal of Physiology and Pharmacology, Vol. 67, pp. 75-78 (1989); Panula et al., Neuroscience, Vol. 82, pp. 993-997 (1997); Haas et al., Behavioural Brain Research, Vol. 66, pp. 41-44 (1995); De Almeida et al., Arch. Int. Pharmacodyn., Vol. 283, pp. 193-198 (1986); Kamei et al., Psychopharmacology, Vol. 102, pp. 312-318 (1990); Kamei et al., Japanese Journal of Pharmacology, Vol. 57, pp. 437-482 (1991); Schwartz et al., Psychopharmacology, The Fourth Generation of Progress, Bloom and Kupfer (eds.), Raven Press, New York, p. 397 (1995); and Wada et al., Trends in Neurosciences, Vol. 14, p. 415 (1991).
- The ability of the compounds of the invention, including but not limited to, those specified in the Examples, to treat epilepsy, and seizures, may be demonstrated by Harada et al., Brain Research Bulletin, Vol. 63, pp. 143-146 (2004); Yokoyama et al., European Journal of Pharmacology, Vol. 234, pp. 129-133 (1993); Yokoyama et al., European Journal of Pharmacology, Vol. 260, p. 23 (1994); Yokoyama et al., CNS Drugs, Vol. 5, p. 321 (1996); Vohora, Life Sciences, Vol. 66, pp. 297-301 (2000); Onodera et al., Progress in Neurobiology, Vol. 42, p. 685 (1994); Chen et al., British Journal of Pharmacology, Vol. 143, pp. 573-580 (2004); Leurs et al., Progress in Drug Research, Vol. 45, pp. 170-165 (1995); Leurs et al., Progress in Drug Research, Vol. 39, p. 127 (1992); Yokoyama et al., CNS Drugs, Vol. 5 (5) pp. 321-330 (1995); Hurukami et al., Meth. Find. Exp. Clin. Pharmacol., Vol. 17 (C), pp. 70-73 (1995); and Yawata et al., Molecular Brain Research, Vol. 132, pp. 13-17 (2004).
- The ability of the compounds of the invention, including but not limited to, those specified in the Examples, to treat allergic rhinitis and asthma, may be demonstrated by McLeod et al., American Journal of Rhinology, Vol. 13, pp. 391-399 (1999); McLeod et al., Allergy, Schering-Plough Research Institute, Kenilworth, N.J., USA.; Hansel et al., “New Drugs for Asthma, Allergy and COPD”, Progress in Respiratory Research, Vol. 31, pp. 133-136 (2001); Delaunois et al., European Journal of Pharmacology, Vol. 277, pp. 243-250 (1995); Dimitriadou et al., Clinical Science, Vol. 87, pp. 151-163 (1994).
- The ability of the compounds of the invention, including but not limited to, those specified in the Examples, to treat motion sickness, dizziness, Meniere's disease, vestibular disorders, and vertigo, may be demonstrated by Pan et al., Methods and Findings in Clinical Pharmacology, Vol. 20(9), pp. 771-777 (1998); O'Neill et al., Methods and Findings in Clinical Pharmacology, Vol. 21(4), pp. 285-289 (1999); Chavez et al., Brain Research, Vol. 1064, pp. 1-9 (2005); Leurs et al., Progress in Drug Research, Vol. 45, pp. 170-165 (1995); and Lozada et al., BioMed Central Neuroscience, Vol. 5, p. 32 (2004).
- The ability of the compounds of the invention, including but not limited to, those specified in the Examples, to treat obesity, diabetes, type II diabetes, Syndrome X, insulin resistance syndrome, and metabolic syndrome, may be demonstrated by Hancock, European Journal of Pharmacology, Vol. 487, pp. 183-197 (2004); Hancock et al., Inflamm. Res., Vol. 53, Supplement 1, S47-S48 (2004); Itoh et al., Biological Psychiatry, Vol. 45(4), pp. 475-481 (1999); Yates et al., Abstracts, Society for Neuroscience, 102.10:219 (November, 2000); Malmlof et al., International Journal of Obesity, Vol. 29, pp. 1402-1412 (2005); and Bjenning et al., Abstracts, International Sendai Histamine Symposium, Sendai, Japan, #P39 (November, 2000); Sakata et al., Brain Research, Vol. 537(1-2), pp. 303-306 (1990).
- The ability of the compounds of the invention, including but not limited to, those specified in the Examples, to treat pain, including neuropathic pain and neuropathy, may be demonstrated by Malmberg-Aiello et al., British Journal of Pharmacology, Vol. 111(4), pp. 1269-1279 (1994); Hriscu, Farmacia, Vol. 49(2), pp. 23-30, (2001).
- The ability of the compounds of the invention, including but not limited to, those specified in the Examples, to treat sleep disorders, including narcolepsy and pathological sleepiness, and jet lag, may be demonstrated by Barbier et al., British Journal of Pharmacology, pp. 1-13 (2004); Monti et al., Neuropsychopharmacology, Vol. 15, pp. 31-35 (1996); Lin et al., Brain Research, Vol. 523, pp. 325-330 (1990); Monti et al., Neuropsychopharmacology, Vol. 15, pp. 31-35 (1996); Ligneau et al., Journal of Pharmacology and Experimental Therapeutics, Vol. 287, pp. 658-666 (1998); Sakai et al., Life Sciences, Vol. 48, pp. 2397-2404 (1991); Mazurkiewicz-Kwilecki et al., Canadian Journal of Physiology and Pharmacology, Vol. 67, pp. 75-78 (1989); Panula et al., Neuroscience, Vol. 44, pp. 465-481 (1998); Wada et al., Trends in Neuroscience, Vol. 14, p. 415 (1991); Monti et al., European Journal of Pharmacology, Vol. 205, p. 283 (1991); Dvorak et al., Journal of Medicinal Chemistry, Vol. 48, pp. 2229-2238 (2005).
- The ability of the compounds of the invention, including but not limited to, those specified in the Examples, to treat drug abuse, may be demonstrated by Clapham et al., European Journal of Pharmacology, Vol. 259 (2), pp. 107-14 (1994). Amphetamine is an abused stimulant in humans. It, and similar abused drugs stimulate locomotor activity in animals, and it has been found that the histamine-3 antagonist thioperamide suppresses the locomotor stimulation induced by amphetamine. Therefore histamine-3 antagonists are likely to be useful for treating drug abuse as may be demonstrated by Clapham et al., European Journal of Pharmacology, Vol. 259 (2), pp. 107-14 (1994).
- The ability of the compounds of the invention, including but not limited to, those specified in the Examples, to treat mood alteration, bipolar disorder, depression, obsessive compulsive disorder, and Tourette's syndrome, may be demonstrated by Lamberti et al., British Journal of Pharmacology, Vol. 123, pp. 1331-1336 (1998); Perez-Garcia et. al., Psychopharmacology, (Berlin) Vol. 142(2), pp. 215-20 (1999).
- The ability of the compounds of the invention, including but not limited to, those specified in the Examples, to treat Parkinson's disease (a disease wherein patients have deficits in the ability to initiate movements, and patients' brains have low dopamine levels) may be demonstrated by Sánchez-Lemus et al., Neuroscience Letters, Vol. 364, pp. 179-184 (2004); Sakai et al., Life Sciences, Vol. 48, pp. 2397-2404 (1991); Fox et al., Journal of Pharmacology and Experimental Therapeutics, Vol. 313, pp. 176-190 (2005); Chen et al., British Journal of Pharmacology, Vol. 143, pp. 573-580 (2004).
- The ability of the compounds of the invention, including but not limited to, those specified in the Examples, to treat medullary thyroid carcinoma, melanoma, polycystic ovary syndrome, may be demonstrated by Polish Med. Sci. Mon., Vol. 4(5), p. 747 (1998); Szelag, Medical Science Monitor, Vol. 4(5), pp. 747-755 (1998); and Fitzsimons et al., Inflammation Res., Vol. 47 (Suppl. 1), pp. S50-S51 (1998).
- Compounds of the invention are particularly useful for treating and preventing a condition or disorder affecting attention-deficit hyperactivity, Alzheimer's disease, or dementia. Compounds of the invention are particularly useful for treating and preventing a condition or disorder affecting schizophrenia or cognitive deficits of schizophrenia. Compounds of the invention are particularly useful for treating and preventing a condition or disorder affecting narcolepsy, sleep disorders, allergic rhinitis, asthma, or obesity.
- Actual dosage levels of active ingredients in the pharmaceutical compositions of this invention can be varied so as to obtain an amount of the active compound(s) that is effective to achieve the desired therapeutic response for a particular patient, compositions and mode of administration. The selected dosage level will depend upon the activity of the particular compound, the route of administration, the severity of the condition being treated, and the condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.
- When used in the above or other treatments, a therapeutically effective amount of one of the compounds of the invention can be employed in pure form, or where such forms exist, in pharmaceutically acceptable salt, ester, amide or prodrug form. Alternatively, the compound can be administered as a pharmaceutical composition containing the compound of interest in combination with one or more pharmaceutically acceptable carriers. The phrase “therapeutically effective amount” of the compound of the invention means a sufficient amount of the compound to treat disorders, at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the compounds and compositions of the invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dosage level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well-known in the medical arts. For example, it is well within the skill of the art to start dosages of the compound at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.
- For treatment or prevention of disease, the total daily dosage of the compounds of this invention administered to a human or lower animal may range from about 0.0003 mg/kg to about 30 mg/kg of body weight. For purposes of oral administration, more preferable doses can be in the range of from about 0.001 mg/kg to about 0.1 mg/kg body weight. If desired, the effective daily dosage can be divided into multiple dosages for purposes of administration. Consequently, single dosage compositions may contain such amounts or submultiples thereof to make up the daily dosage.
- The compounds of the invention can be better understood in connection with the following synthetic schemes and methods, which illustrate a means by which the compounds can be prepared.
- Abbreviations which have been used in the descriptions of the schemes and the Examples that follow are: Xantphos for 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene, [161265-03-8]; BINAP for 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl; Boc for butyloxycarbonyl; EtOAc for ethyl acetate; HPLC for high pressure liquid chromatography; IPA for isopropyl alcohol; Me for methyl; MeOH for methanol; Ms for methanesulfonyl; Pd for palladium; tBu for tert-butyl; TEA for triethylamine; TFA for trifluoroacetic acid; THF for tetrahydrofuran; and Ts for para-toluenesulfonyl; dba for dibenzylidine acetone; DCM for dichloromethane, NH4OH for saturated aqueous ammonium hydroxide; rt for room temperature or ambient temperature suitably ranging from 17-30° C. Copper iodide is CuI; palladium acetate is Pd(OAc)2. Emrys process vial is a microwave process vial (10 ml or 30 ml glass vial with sealed cap) from PersonalChemistry AB (Uppsala). All microwave irradiation experiments were carried out using the Emrys synthesizer from PersonalChemistry AB (Uppsala). All experiments were carried out in sealed microwave process vials utilizing the standard absorbance level (300 W maximum power). If not stated otherwise, reaction times under microwave conditions reflect total irradiation times counted from the beginning of the irradiation. As identifiers of compounds available from descriptions reported in the literature or available commercially, CAS numbers may be used. CAS numbers are identifier numbers assigned to compounds by Chemical Abstracts Service of the American Chemical Society, and are well-known to those of ordinary skill in the art.
- The compounds of this invention can be prepared by a variety of synthetic procedures. Specific procedures for the preparation of the compounds of formula (I) are given.
- The following Reference Examples describe synthesis of compounds used for preparation of compounds as described in the Examples. Such methods are intended only to provide examples of how such compounds can be obtained and are not intended to provide an exhaustive list of how to provide the desired compound.
- A reactor was charged with 10 g of R-methylbenzylamine, 100 mL of EtOAc, and 9.19 g of Et3N. Methyl bromoacetate (15.15 g) was added and the mixture was heated to 50-60° C. for 10 hours with stirring. The mixture was then cooled to ambient temperature, then washed with 50 mL of water followed by 50 mL of 15% NaCl solution, to provide 100 g of an EtOAc solution which contained 15 g of (1-phenyl-ethylamino)-acetic acid methyl ester (96% yield).
- A solution of (1-(R)-phenyl-ethylamino)-acetic acid methyl ester (21.7 g of a solution in EtOAc) was concentrated, and the residue was taken up in 24 mL of water and heated at reflux for 13 hours. Upon completion, the mixture was concentrated under reduced pressure and 30 mL of isopropanol was added. The resulting precipitate was filtered and rinsed with 10 mL of isopropanol then dried under reduced pressure to provide 2.4 g of the title compound.
- A solution of (1-(R)-phenyl-ethylamino)-acetic acid (25.6 g) in 384 mL of toluene was heated to 90° C. To this 170 g (1.1 equivalents) of a 15.84 wt. % solution of allyl-(2-oxo-ethyl)-carbamic acid ethyl ester (U.S. Pat. No. 5,071,999) in toluene, was added over 20 minutes and the mixture was stirred at 90° C. for 14 hours then at 95° C. for 12 hours. After cooling, the product was extracted with 2×115 g of 20% citric acid solution. The citric acid solution was diluted with 205 mL of isopropyl acetate, and the mixture was neutralized with a solution of 51.2 g K2CO3 in 120 g water, and thoroughly shaken. The layers were separated, and the aqueous layer was extracted again with 102 mL of isopropyl acetate. The organic extracts were combined and distilled under reduced pressure to provide an oil which was then diluted with 125 mL of MeOH to provide 140 g (100% yield) of the title compound as a 30% by weight solution in MeOH.
- 5% palladium hydroxide on activated carbon (13.9 g, 50% w/w in water) was added to a pressure reactor. The product of Example A3 (as 506.8 g of a 25.9 wt % solution of ethyl 1-((R)-1-phenylethyl)hexahydropyrrolo[2,3-c]pyrrole-5(1H)-carboxylate (131.3 g) in MeOH was added, followed by a MeOH rinse (37 g). The mixture was heated to 50° C. under an atmosphere of hydrogen (40 psi) for 4 hours. The mixture was filtered through HYFLO Filter Aid (HYFLO is a registered trademark of Celite Products Company of Los Angeles, Calif.) and rinsed with 200 mL of MeOH to provide a solution containing 78.9 g of the title compound.
- A solution of 150 g of ethyl hexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxylate (˜11.2% wt in MeOH) was heated to 60° C. To this was added a solution of D-dibenzoyltartaric acid mono-hydrate (231.5 g) dissolved in MeOH (591 mL+95 mL rinse), and the mixture was stirred at 60±5° C. for 2 hours during which time crystallization occurred. The slurry was cooled to 18° C. over 6 hours, and the product was collected by filtration and rinsed with MeOH (2×330 mL). The product was dried at 40-45° C. to provide 198 g of the title compound. Chiral HPLC analysis of the Cbz-derivative ((3aR,6aR)-1-benzyl 5-ethyl hexahydropyrrolo[3,4-b]pyrrole-1,5-dicarboxylate. The Cbz group is an abbreviation for the carbobenzyloxy protecting group of the product and indicates that the product was obtained with 99% enantiomeric excess.
- To a solution of (3aR,6aR)-hexahydro-pyrrolo[3,4-b]pyrrole-1-carboxylic acid tert-butyl ester (18.31 g, 0.86 mol) in MeOH (450 ml) was added paraformaldehyde (52 g, 1.72 mole), and the mixture was stirred at room temperature for 1 hour. Sodium cyanoborohydride was then added, and the mixture was stirred at room temperature for 10 hours, diluted with 1N NaOH (450 ml), extracted with dichloromethane (5×200 ml). The combined organic layers were dried (Na2SO4), filtered and concentrated to provide the title compound. 1H NMR (300 MHz, DMSO-d6) δ ppm 4.18 (m, 1H) 3.47-3.59 (m, 1H) 3.34-3.46 (m, 2H) 2.75-2.90 (m, 1H) 2.71 (m, 1H) 2.44-2.60 (m, 2H) 2.29 (s, 3H) 1.89-2.06 (m, 1H) 1.65-1.81 (m, 1H) 1.42-1.49 (m, 9H). MS: (M+H)+=226.
- (3aR,6aR)-hexahydro-pyrrolo[3,4-b]pyrrole-1-carboxylic acid tert-butyl ester (CAS #370880-09-4) may be prepared as described in Schenke et al, “Preparation of 2,7-Diazabicyclo[3.3.0]octanes”, U.S. Pat. No. 5,071,999 (1991), which provides a racemate which may be resolved by chromatography on a chiral column or by fractional crystallization of diasteromeric salts, or as described in Basha et al., “Substituted Diazabicycloalkane Derivatives”, U.S. Patent Publication Number 2005/0101602 (2005).
- To a solution of the product of Example A6 (20.8 g, 0.86 mole) in MeOH (450 ml) was added aqueous 3N HCl (300 ml). The mixture was stirred at room temperature overnight, then concentrated to dryness at 30° C. under vacuum. The residue was treated with aqueous 1N NaOH to obtain a pH of 9-10. The mixture was concentrated to dryness. The crude material was purified by chromatography (eluting with a mixture of 10% MeOH and 1% NH4OH in dichloromethane) to provide the title compound. 1H NMR (300 MHz, CDCl3) δ ppm 4.12-4.17 (m, 1H) 3.31-3.43 (m, 1H) 3.19-3.30 (m, 1H) 3.12 (d, J=11.53 Hz, 1H) 2.88-3.01 (m, 1H) 2.69 (dd, J=9.49, 2.37 Hz, 1H) 2.40-2.52 (m, 2H) 2.33 (s, 3H) 2.12-2.28 (m, 1H) 1.82-1.95 (m, 1H). MS: (M+H)+=127.
- The product of Example A7 (2.30 g, 18.2 mmole), 1,4-dibromobenzene (5.16 g, 20.9 mmole), tris(dibenzylideneacetone)dipalladium (340 mg, 0.36 mmole), racemic-2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (460 mg, 0.73 mmole) and sodium tert-butoxide (2.63 g, 27.3 mmole) were dissolved in 20 ml of toluene and heated to 70° C. under N2 for 16 hours. The mixture was cooled to room temperature, diluted with water and extracted with dichloromethane (5×). The combined organics were dried over sodium sulfate, filtered and concentrated and purified by chromatography (eluting with a mixture of 5% MeOH in dichloromethane) to provide the title compound. 1H NMR (300 MHz, CDCl3) δ ppm 7.25-7.30 (m, 2H) 6.41-6.46 (m, 2H) 4.07 (m, 1H) 3.47 (ddd, J=9.1, 7.7, 5.9 Hz, 1H) 3.19 (dt, J=8.9, 7.3 Hz, 1H) 2.95 (m, 1H) 2.68 (dd, J=9.0, 3.0 Hz, 1H) 2.55-2.60 (m, 3H) 2.32 (s, 3H) 2.13-2.22 (m, 1H) 1.88-1.98 (m, 1H). MS: (M+H)+=281/283.
- The compounds and processes of the invention will be better understood by reference to the following Examples, which are intended as an illustration of and not a limitation upon the scope of the invention.
- Unless otherwise described, reactions were carried out under ambient conditions (ranging from 17-27° C.), under nitrogen. Unless otherwise described, “column chromatography” means flash chromatography carried out using silica gel, a technique well-known to those of ordinary skill in the art of organic synthesis.
- The title compound was prepared according to the procedure described in Example A8, substituting 4,4′-dibromobiphenyl for 1,4-dibromobenzene. 1H NMR (300 MHz, CDCl3) δ ppm 7.39-7.53 (m, 6H) 6.60-6.66 (m, 2H) 4.17-4.23 (m, 1H) 3.52-3.61 (m, 1H) 3.26-3.35 (m, 1H) 2.98-3.05 (m, 1H) 2.70-2.80 (m, 2H) 2.58-2.64 (m, 2H) 2.38 (s, 3H) 2.15-2.26 (m, 1H) 1.97 (m, 1H). MS: (M+H)+=357/359.
- The product of Example 1A (4.54 g, 12.6 mmole), 3(2H)-pyridazinone (2.41 g, 25.2 mmole), copper powder (1.60 g, 25.2 mmole) and potassium carbonate (5.21 g, 37.7 mmole) were dissolved in 63 ml of quinoline and heated at 150° C. under N2 for 48 hours. The mixture was cooled to room temperature, diluted with hexane (15 ml) and filtered through a CELITE filter (CELITE is a registered trademark of Johns-Manville Corporation of Denver, Colo.). The filtrate was concentrated under reduced pressure and the residue was purified by chromatography (eluting first with diethyl ether, followed by dichloromethane, then elution with a mixture of 5% MeOH in dichloromethane) to provide the title compound, 2-{4′-[(3aR,6aR)-5-methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl]-1,1′-biphenyl-4-yl}pyridazin-3(2H)-one. 1H NMR (300 MHz, CDCl3) δ ppm 7.91 (dd, J=3.73, 1.70 Hz, 1H) 7.61-7.65 (m, 4H) 7.51 (d, J=8.48 Hz, 2H) 7.25 (dd, dd, J=9.40, 4.07 Hz, 1H) 7.07 (dd, J=9.49, 1.70 Hz, 1H) 6.64 (d, J=8.81 Hz, 2H) 4.19-4.27 (m, 1H) 3.54-3.64 (m, 1H) 3.28-3.38 (m, 1H) 3.00-3.11 (m, 1H) 2.56-2.85 (m, 4H) 2.40 (s, 3H) 2.10-2.29 (m, 1H) 1.89-2.05 (m, J=6.78 Hz, 1H); MS (M+H)+=373. The solid (3aR,6aR)-2-[4′-(5-methyl-hexahydro-pyrrolo[3,4-b]pyrrol-1-yl)-biphenyl-4-yl]-2H-pyridazin-3-one obtained showed a melting range of 204-207° C. (dec.).
- Alternatively, (3aR,6aR)-2-[4′-(5-methyl-hexahydro-pyrrolo[3,4-b]pyrrol-1-yl)-biphenyl-4-yl]-2H-pyridazin-3-one, the product of Example 1B, can be prepared according to the following procedure:
- The product of Example A5 (205 g) and CH2Cl2 (1 L) were combined and cooled to 0° C. 1.54 L of a 20% KOH solution was cooled to 0° C. then slowly added to the salt slurry, and the biphasic reaction mixture was stirred vigorously at 0° C. After 2.75 hours, the layers were separated and the aqueous layer was extracted with CH2Cl2 (1 L). The organic layers were combined and concentrated under reduced pressure, then chased with toluene (1.6 L) to provide 386 g of a 19 wt % solution of product (100%).
- To a vessel containing 4,4′-dibromobiphenyl (12.48 g, 2.0 equiv.) and cesium carbonate (13.04 g, 2.0 eq.) was added the product of Example 1C (17.9 wt %, 20.6 g, 1.0 eq.) after which the vessel was evacuated and purged. A catalyst solution was prepared in a separate vessel by mixing Xantphos (0.77 g, 0.067 eq.) and palladium (II) acetate (0.22 g, 0.049 eq.) and degassed after which 17.3 g of toluene was added with stirring.
- The catalyst solution was added to the vessel containing the 4,4′-dibromobiphenyl, cesium carbonate, and the product of Example 41C and the mixture was heated to 98° C. for 12 hours. The mixture was cooled to 20° C. and 80 g of dichloromethane was added. The resulting mixture was stirred and then filtered to remove the catalyst. The resulting solution was concentrated under reduced pressure and the residue was purified by column chromatography to yield 5.65 g of the title compound.
- A mixture of 1.98 g of copper (I) iodide (10.4 mmole, 0.10 eq.), 1.66 g of 8-hydroxyquinoline (11.44 mmole, 0.11 eq.), 4.0 g of potassium carbonate (28.94 mmole, 0.29 eq.) in 18.8 g of dimethylformamide (DMF) was mixed at ambient temperature. The mixture was added to another flask containing 41.6 g of the product of Example 1D (100.16 mmole, 1.00 eq.), 23.6 g of potassium carbonate (170.75 mmole, 1.70 eq.), and 14.4 g of 3(2H)-pyridazinone (149.86 mmole, 1.50 eq.). Additional DMF (226 g) was used to transfer the catalyst slurry. The resulting mixture was deoxygenated then heated to 140° C. for about 18 hours. After cooling to ambient temperature, the mixture was diluted with 567 g of THF and 384 g of 10% NaCl solution. The mixture was filtered to remove excess salts and the aqueous phase was separated and back extracted with an additional 177 g of THF. The combined organic phases were then washed with 10% NaCl solution (3×384 g). The organic phase was concentrated under reduced pressure and MeOH (253 g) was added and the contents were concentrated under reduced pressure. After adding additional MeOH (158 g), the contents were cooled to 0° C., filtered, and washed with cold MeOH. The resulting solids were transferred to a vacuum oven to yield 35.31 g (81.9% yield). Mass Spectroscopy: 431.5 (m.w. 430.5). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.15 (s, 3H), 1.78-1.88 (m, 1H), 2.10 (ddd, J=12.49, 6.17, 6.04 Hz, 1H), 3.03 (s, 1H), 3.24-3.35 (m, 5H), 3.53 (ddd, J=9.23, 6.86, 6.69 Hz, 2H), 3.67 (s, 1H), 4.00 (s, 2H), 4.22 (s, 1H), 6.63 (d, J=8.51 Hz, 2H), 7.07 (dd, J=9.47, 1.51 Hz, 1H), 7.48 (dd, J=9.47, 3.84 Hz, 1H), 7.53-7.60 (m, 4H), 7.68 (d, J=8.64 Hz, 2H), 8.06 (dd, J=3.84, 1.51 Hz, 1H). 13C NMR (100 MHz, DMSO-d6) δ ppm 14.79 (CH3), 28.89 (CH2), 47.71 (CH2), 60.24 (CH2), 112.34 (CH), 124.87 (CH), 125.27 (CH), 126.02 (C), 126.89 (CH), 130.05 (CH), 131.69 (CH), 136.87 (CH), 138.78 (C), 139.31 (C), 145.61 (C), 153.53 (C), 158.64 (C).
- A mixture of the product of Example 1E (7.50 g, 17.42 mmol) in 33% HBr in acetic acid (37 mL, 205.57 mmol, 11.8 equivalents) was heated to 65-70° C. for at least 6 hours while monitored by HPLC analysis for completion. When reaction is complete, the mixture is cooled to not more than 45° C. and is diluted with MeOH (111 mL). The mixture was cooled to 20-25° C., the product is collected by filtration and is washed with fresh MeOH (50 mL). The wet cake is dried in the vacuum oven at not more than 55° C. to provide the title compound (7.25 g, 94.8%).
- To a stirred solution of the product of Example 1F (13.80 g, 31.41 mmol) in dimethylacetamide (500 mL) was added a solution of 37% aqueous formaldehyde (7.2 mL, 94.23 mmol, 3.0 equivalents) followed by sodium triacetoxyborohydride (20.0 g, 94.23 mmol, 3.0 equivalents). The mixture was stirred at 25+/−5° C. for 30 minutes during which the starting material was consumed, giving a clear solution. The mixture was diluted with 1N HCl (94 mL, 94 mmol, 3 equivalents) and stirred for one hour. The mixture was adjusted to pH 9.0+/−0.5 with 1N NaOH (335 mL). The mixture was stirred for 1 hour then filtered. The wet cake was washed with water and dried in a vacuum oven at about 50° C. to provide the title compound, 2-[4′-(3aR,6aR)-(5-methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl)-1,1′-biphenyl-4-yl]pyridazin-3(2H)-one (10.40 g, 88.9%).
- A solution of the product from Example 1G (5 g, 13.44 mmol) in DCM (80 mL) and MeOH (40 mL) was treated with hydrogen peroxide (5.2 mL, 30% in H2O, 53.8 mmol). The mixture was heated to 50° C. for 48 hours. The mixture was concentrated under reduced pressure to a smaller volume while still in a solution. The solution was loaded onto an ANALOGIX SuperFlash silica gel column (ANALOGIX is a registered trademark of Analogix Inc. of Burlington, Wis.) and eluted with NH4OH/MeOH/DCM (1/10/90) to obtain the faster moving component (comparing with Example 1I) as the title product. 1H NMR (300 MHz, DMSO) δ ppm 8.06 (m, 1H), 7.69 (d, J=9 Hz, 2H), 7.57 (d, J=9 Hz, 4H), 7.50 (d, J=6 Hz, 1H), 7.08 (dd, dd, J=9, 4.0 Hz, 1H), 6.70 (d, J=9 Hz, 2H), 4.72 (d, J=6 Hz, 1H), 3.75-3.82 (m, 1H), 3.52-3.59 (m, 2H), 3.36-3.45 (m, 3H), 3.15-3.21 (m, 1H), 3.14 (s, 3H), 2.05-2.12 (m, 1H), 1.80-1.86 (m, 1H); MS (DCI,) M+=388.
- A solution of the product from Example 1G (5 g, 13.44 mmol) in DCM (80 mL) and MeOH (40 mL) was treated with hydrogen peroxide (5.2 mL, 30% in H2O, 53.8 mmol). The mixture was heated to 50° C. for 48 hours. The mixture was concentrated under reduced pressure to a smaller volume while still in a solution. The solution was loaded onto an ANALOGIX SuperFlash silica gel column (ANALOGIX is a registered trademark of Analogix Inc. of Burlington, Wis.) and eluted with NH4OH /MeOH/DCM (1/10/90) to obtain the slower moving component (comparing with Example 1H) as the title product. 1H NMR (300 MHz, DMSO) δ ppm 8.07 (m, 1H), 7.70 (d, J=9 Hz, 2H), 7.57 (d, J=9 Hz, 4H), 7.50 (d, J=6 Hz, 1H), 7.08 (dd, dd, J=9, 4.0 Hz, 1H), 6.65 (d, J=9 Hz, 2H), 4.48-4.54 (m, 1H), 3.81-3.87 (m, 1H), 3.66-3.74 (m, 2H), 3.36-3.42 (m, 2H), 3.24 (m, 1H), 3.09 (s, 3H), 2.11-2.17 (m, 1H); MS (DCI,) M+=388.
- A mixture of tert-butyl (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxylate (1, 1.5 g, 7.0 mmol), 1,4-dibromobenzene (2.8 g, 20.4 mmol), Pd2(dba)3 (275 mg, 0.3 mmol), BINAP (375 mg, 0.6 mmol) and sodium tert-butoxide (1.93 g, 20.0 mmol) were placed in glass microwave tubes and then purged three times with N2 gas, followed by the addition of toluene (45 mL). The mixture was heated to 140° C. for 15 minutes in a microwave reactor. The mixture was then cooled to room temperature, was filtered, and the crude mixture was purified via chromatography (SiO2, O-25% EtOAc:hexanes) to provide the title compound. 1H NMR (300 MHz, CDCl3): δ=7.30 ppm (m, 2H), 7.39 (m, 2H), 4.11 (m, 1H), 3.57 (m, 3H), 3.31 (m, 3H), 2.99 (m, 1H), 2.15 (m, 1H), 1.92 (m, 1H), 1.43 (s, 9H). MS (ESI, M+1): 310.9.
- Tert-butyl (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxylate (CAS #370882-39-6) may be prepared by the method described in Schrimpf et al., “Diazabicyclic Central Nervous System Active Agents”, WO 2001/081347(A2) (2001).
- To a solution of (3aR,6aR)-tert-butyl 1-(4-bromophenyl)hexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxylate (1.86 g, 5.1 mmol) in CH2Cl2 (50 mL) at 23° C. was added TFA (8 mL) and the mixture was allowed to stir for 2 hrs. The solvents were removed under vacuum and the residue was taken up in MeOH (50 mL) followed by the addition of formaldehyde (37%, 3 mL, 40 mmol) and NaBH3CN (950 mg, 15.1 mmol). The mixture was stirred at 23° C. for 10 hours, concentrated under reduced pressure and the residue was dissolved in CH2Cl2 (100 mL), washed sequentially with water (2×50 mL), brine (1×30 mL), and dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product mixture was purified via chromatography (SiO2, O-10% MeOH in CH2Cl2) to provide the title compound. 1H NMR (300 MHz, CDCl3): δ=7.28 ppm (m, 2H), 6.44 (m, 2H), 4.05 (m, 1H), 3.45 (m, 1H), 3.19 (m, 1H), 2.94 (m, 1H), 2.67 (m, 1H), 2.52 (m, 3H), 2.30 (s, 3H), 2.16 (m, 1H), 1.95 (m, 1H). MS (ESI, M+1): 280.8.
- (3aR,6aR)-1-(4-bromophenyl)-5-methyloctahydropyrrolo[3,4-b]pyrrole (1.0 g, 3.6 mmol), bis(pinacolato)diboron (4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane, (1.0 g, 3.9 mmol), Pd(dppf)Cl2CH2Cl2 (100 mg, 0.12 mmol) and KOAc (1150 mg, 11.7 mmol) were placed in a sealed microwave reaction tube, and purged three times with N2 gas. Dioxane (20 mL) was added, and the mixture was heated at 150° C. for 15 minutes. After cooling down to 23° C., the mixture was filtered, and solvent was removed under reduced pressure. The mixture was then purified via chromatography (SiO2, 10-60% EtOAc in hexanes) to provide the title compound. 1H NMR (300 MHz, CDCl3): δ=7.67 ppm (m, 2H), 6.54 (m, 2H), 4.21 (m, 1H), 3.52 (m, 1H), 3.33 (m, 1H), 2.97 (m, 1H), 2.67 (m, 2H), 2.57 (m, 2H), 2.34 (br, 3H), 2.15 (m, 1H), 1.95 (m, 1H), 1.32 (s, 12H). MS (ESI, M+1): 329.1.
- 3-pyridazinone (300 mg, 3.1 mmol), 2,5-dibromopyridine (1.0 g, 4.2 mmol), copper powder (200 mg, 3.1 mmol) and K2CO3 (1.29 g, 9.3 mmol) were placed in a sealed microwave tube, and purged three times with N2 gas, followed by the addition of pyridine (15 mL). The mixture was heated to 120° C. in a microwave reactor for 40 minutes. The mixture was concentrated under reduced pressure after which the residue was taken up in CH2Cl2/MeOH, filtered and concentrated under reduced pressure. The crude mixture was purified via chromatography (SiO2, 10-80% EtOAc in hexanes) to provide the title compounds.
- 2-(5-bromopyridin-2-yl)pyridazin-3(2H)-one. 1H NMR (300 Mhz, CDCl3): δ=8.72 ppm (s(br), 1H), 7.99 (m, 2H), 7.68 (d(br), J=8.4 Hz, 1H), 7.29 (dd (br), J=8.4, 3.7 Hz, 1H), 7.07 (dd, J=9.5, 1.7 Hz, 1H). MS (ESI, M+1): 253.8.
- 2-(6-bromopyridin-3-yl)pyridazin-3(2H)-one. 1H NMR (300 MHz, CDCl3): δ=8.76 ppm (d, J=3.4 Hz, 1H), 7.98 (dd, J=8.5, 2.7 Hz, 1H), 7.94 (dd, J=2.7, 1.7 Hz, 1H), 7.59 (d, J=8.4 Hz, 1H), 7.29 (dd, J=8.4, 3.4 Hz, 1H), 7.06 (dd, J=8.5, 1.7 Hz, 1H). MS (ESI, M+1): 253.8.
- (3aR,6aR)-5-methyl-1-(4-(4,4,5,5-tetramethyl-1,3-dioxaborolan-2-yl)phenyl)octa-hydro-pyrrolo[3,4-b]pyrrole (50 mg, 0.15 mmol), 2-(5-bromopyridin-2-yl)pyridazin-3(2H)-one (42 mg, 0.17 mmol), Pd(PPh3)2Cl2 (11 mg, 0.01 mmol), 2-(dicyclohexylphosphino)biphenyl (5.6 mg, 0.016 mmol) and Na2CO3 (1M, 225 μL) were placed in a microwave tube, purged with N2 and a mixture of solvents (EtOH:dioxane=1:1, 1 mL) was added. The mixture was heated to 140° C. in a microwave reactor for 15 minutes, cooled to ambient temperature, was filtered, and concentrated under reduced pressure. The residue was purified via chromatography (SiO2, O-10% MeOH in CH2Cl2) to provide the title compound, 2-(5-(4-((3aR,6aS)-5-methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl)phenyl)pyridin-2-yl)pyridazin-3(2H)-one. 1H NMR (300 MHz, CDCl3): δ=8.82 ppm (d, J=2.8 Hz, 1H), 7.98 (m, 2H), 7.73 (d, J=8.2 Hz, 1H), 7.52 (m, 2H), 7.28 (dd, J=10.1, 3.7 Hz, 1H), 7.09 (dd, J=10.1, 1.7 Hz, 1H), 6.67 (m, 2H), 4.39 (m, 1H), 3.66 (m, 1H), 3.30 (m, 3H), 2.87 (m, 2H), 2.59 (s(br), 3H), 2.23 (m, 2H), 2.05 (m, 1H). MS (ESI, M+1): 374.2.
- A solution of the product from Example 2E (23 mg, 0.062 mmol) in DCM (0.5 mL) and MeOH (1 mL) was treated with hydrogen peroxide (0.04 mL, 30% in H2O, 0.24 mmol). The mixture was screw-capped in a 4 mL vial and heated to 50° C. for 24 hours. The mixture was concentrated under reduced pressure to a smaller volume while still in a solution. The solution was loaded onto an ANALOGIX SuperFlash silica gel column (ANALOGIX is a registered trademark of Analogix Inc. of Burlington, Wis.) and eluted with NH4OH/MeOH/DCM (1/10/90) to obtain the faster moving component (comparing with Example 2G) as the title product, (3aR,5R,6aR)-5-methyl-1-(4-(6-(6-oxopyridazin-1(6H)-yl)pyridin-3-yl)phenyl)octahydropyrrolo[3,4-b]pyrrole 5-oxide. 1H NMR (500 MHz, METHANOL-D4) δ ppm 1.25-1.31 (m, 1H) 1.94-2.00 (m, J=19.22 Hz, 1H) 2.21-2.29 (m, J=37.84 Hz, 1H) 3.26-3.28 (m, 3H) 3.47 (d, J=27.77 Hz, 1H) 3.55 (d, J=25.33 Hz, 1H) 3.66 (none, 1H) 4.03 (dd, J=11.44, 8.09 Hz, 1H) 6.78 (d, J=8.54 Hz, 1H) 7.12 (dd, J=9.76, 1.53 Hz, 1H) 7.53 (dd, J=9.61, 3.81 Hz, 1H) 7.62 (d, J=8.85 Hz, 2H) 7.65 (d, J=8.54 Hz, 1H) 8.19 (dd, J=8.24, 2.44 Hz, 1H) 8.76 (d, J=2.14 Hz, 1H). MS (DCI,) M+=389.
- A solution of the product from Example 2E (23 mg, 0.062 mmol) in DCM (0.5 mL) and MeOH (1 mL) was treated with hydrogen peroxide (0.04 mL, 30% in H2O, 0.24 mmol). The mixture was screw-capped in a 4 mL vial and heated to 50° C. for 24 hours. The mixture was concentrated under reduced pressure to a smaller volume while still in a solution. The solution was loaded onto an ANALOGIX SuperFlash silica gel column (ANALOGIX is a registered trademark of Analogix Inc. of Burlington, Wis.) and eluted with NH4OH/MeOH/DCM (1/10/90) to obtain the slower moving component (comparing with Example 2F) as the title product, (3aR,5S,6aR)-5-methyl-1-(4-(6-(6-oxopyridazin-1(6H)-yl)pyridin-3-yl)phenyl)octahydropyrrolo[3,4-b]pyrrole 5-oxide. (3aR,5S,6aR)-5-methyl-1-(4-(6-(6-oxopyridazin-1(6H)-yl)pyridin-3-yl)phenyl)octahydropyrrolo[3,4-b]pyrrole 5-oxide. 1H NMR (501 MHz, METHANOL-D4) δ ppm 1.27-1.30 (m, 1H) 2.25-2.30 (m, 1H) 3.25 (s, 3H) 3.35-3.48 (m, 3H) 3.52-3.57 (m, J=21.09 Hz, 1H) 3.71 (q, 1H) 3.82 (dd, J=11.41, 8.34 Hz, 1H) 4.02 (dd, J=12.08, 6.52 Hz, 1H) 4.62-4.67 (m, J=19.36 Hz, 1H) 6.73 (d, J=8.82 Hz, 1H) 7.09 (dd, J=9.39, 1.53 Hz, 1H) 7.49 (dd, J=9.39, 3.83 Hz, 1H) 7.59 (d, J=8.82 Hz, 1H) 7.61 (d, J=8.43 Hz, 1H) 8.03 (dd, J=3.83, 1.53 Hz, 1H) 8.15 (dd, J=8.24, 2.49 Hz, 1H) 8.72 (d, J=2.11 Hz, 1H). MS (DCI) M+=389.
- The invention also provides pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula (I), or suitable salts and polymorphs thereof, in combination with a pharmaceutically acceptable carrier. The compositions comprise compounds of the invention formulated together with one or more non-toxic pharmaceutically acceptable carriers. The pharmaceutical compositions can be formulated for oral administration in solid or liquid form, for parenteral injection, or for rectal administration.
- The term “pharmaceutically acceptable carrier”, as used herein, means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Some examples of materials which can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants that can also be present in the composition, according to the judgment of one skilled in the art of formulations.
- The pharmaceutical compositions of this invention can be administered to humans and other mammals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments or drops), bucally or as an oral or nasal spray. The term “parenterally”, as used herein, refers to modes of administration, which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous, intraarticular injection and infusion.
- Pharmaceutical compositions for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol, and the like, and suitable mixtures thereof), vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate, or suitable mixtures thereof. Suitable fluidity of the composition may be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
- These compositions may also contain adjuvants such as preservative agents, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example, sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form may be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.
- In some cases, in order to prolong the effect of a drug, it is often desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
- Suspensions, in addition to the active compounds, may contain suspending agents, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, tragacanth, and mixtures thereof. If desired, and for more effective distribution, the compounds of the invention can be incorporated into slow-release or targeted-delivery systems such as polymer matrices, liposomes, and microspheres. They may be sterilized, for example, by filtration through a bacteria-retaining filter or by incorporation of sterilizing agents in the form of sterile solid compositions, which may be dissolved in sterile water or some other sterile injectable medium immediately before use.
- Injectable depot forms are made by forming microencapsulated matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations also are prepared by entrapping the drug in liposomes or microemulsions, which are compatible with body tissues.
- The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.
- Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic, parenterally acceptable diluent or solvent such as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, one or more compounds of the invention is/are mixed with at least one inert pharmaceutically acceptable carrier, such as sodium citrate or dicalcium phosphate, and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and salicylic acid; b) binders such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia; c) humectants such as glycerol; d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; e) solution retarding agents such as paraffin; f) absorption accelerators such as quaternary ammonium compounds; g) wetting agents such as cetyl alcohol and glycerol monostearate; h) absorbents such as kaolin and bentonite clay; and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
- Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using lactose or milk sugar as well as high molecular weight polyethylene glycols.
- The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well-known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract in a delayed manner. Examples of materials which can be useful for delaying release of the active agent can include polymeric substances and waxes.
- Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
- Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. A desired compound of the invention is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.
- The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- Powders and sprays can contain, in addition to the compounds of this invention, lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons. Compounds of the invention may also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes may be used. The present compositions in liposome form may contain, in addition to the compounds of the invention, stabilizers, preservatives, and the like. The preferred lipids are the natural and synthetic phospholipids and phosphatidylcholines (lecithins) used separately or together.
- Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.Y., (1976), p. 33, et seq.
- Dosage forms for topical administration of a compound of this invention include powders, sprays, ointments and inhalants. The active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers or propellants, which can be required. Opthalmic formulations, eye ointments, powders and solutions are contemplated as being within the scope of this invention. Aqueous liquid compositions comprising compounds of the invention also are contemplated.
- The compounds of the invention can be used in the form of pharmaceutically acceptable salts, esters, or amides derived from inorganic or organic acids. The phrase “pharmaceutically acceptable salts, esters and amides”, as used herein, refers to carboxylate salts, amino acid addition salts, zwitterions, esters and amides of compounds of formula (I) which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.
- The term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well-known in the art. The salts can be prepared in situ during the final isolation and purification of the compounds of the invention or separately by reacting a free base function with a suitable organic acid or inorganic acid.
- Representative acid addition salts include, but are not limited to, ascorbic acid, (D)-tartaric acid, (L)-tartaric acid, phosphoric acid, salicylic acid, sulfuric acid, trifluoroacetic acid, and hydrochloric acid.
- The basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates such as dimethyl, diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; arylalkyl halides such as benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained.
- Basic addition salts can be prepared in situ during the final isolation and purification of compounds of this invention by reacting a carboxylic acid-containing moiety with a suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation or with ammonia or an organic primary, secondary or tertiary amine. Pharmaceutically acceptable salts include, but are not limited to, cations based on alkali metals or alkaline earth metals such as lithium, sodium, potassium, calcium, magnesium, and aluminum salts, and the like, and nontoxic quaternary ammonia and amine cations including ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, and the like. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.
- To determine the effectiveness of representative compounds of this invention as histamine-3 receptor ligands, the following tests were conducted according to previously described methods (see Arrang et al, “Histamine H3 Receptor Binding Sites in Rat Brain Membranes:Modulations by Guanine Nucleotides and Divalent Cations”, European Journal of Pharmacology, Vol. 188, pp. 219-227 (1990); Tedford et al., “Pharmacological Characterization of GT-2016, A Non-Thiourea-Containing Histamine H3 Receptor Antagonist: In Vitro and In Vivo Studies”, The Journal of Pharmacology and Experimental Therapeutics, Vol. 275, pp. 598-604 (1995); Leurs et al., “Histamine Homologues Discriminating Between Two Functional H3-Receptor Assays. Evidence for H3 Receptor”, Journal of Pharmacology and Experimental Therapeutics, Vol. 276, No. 3, pp. 1009-1015 (1996); and Cheng et al., “Relationship Between the Inhibition Constant (K1) and the Concentration of Inhibitor which Causes 50% Inhibition (150) of an Enzymatic Reaction”, Biochemical Pharmacology, Vol. 22., pp. 3099-3108 (1973)).
- The rat histamine-3 receptor was cloned and expressed in cells, and competition binding assays carried out, according to methods previously described (see Esbenshade et al., “Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and Selective Histamine H3 Receptor Antagonist with Drug-Like Properties”, Journal of Pharmacology and Experimental Therapeutics, Vol. 313, pp. 165-175, (2005); Esbenshade et al., “Pharmacological and Behavioral Properties of A-349821, a Selective and Potent Human Histamine H3 Receptor Antagonist”, Biochemical Pharmacology, Vol 68, pp. 933-945 (2004); Krueger et al., “G Protein-Dependent Pharmacology of Histamine H3 Receptor Ligands: Evidence for Heterogeneous Active State Receptor Conformations”, Journal of Pharmacology and Experimental Therapeutics, Vol. 314, pp. 271-281 (2005)). Membranes were prepared from C6 or HEK293 cells, expressing the rat histamine-3 receptor, by homogenization on ice in TE buffer (50 mM Tris-HCl buffer, pH 7.4, containing 5 mM EDTA), 1 mM benzamidine, 2 μg/ml aprotinin, 1 μg/ml leupeptin, and 1 μg/ml pepstatin. The homogenate was centrifuged at 40,000 g for 20 minutes at 4° C. This step was repeated, and the resulting pellet was resuspended in TE buffer. Aliquots were frozen at −70° C. until needed. On the day of assay, membranes were thawed and diluted with TE buffer.
- Membrane preparations were incubated with [H3]-N-α-methylhistamine (0.5-1.0 nM) in the presence or absence of increasing concentrations of ligands of formula (I) and formula (II) for histamine-3 receptor competition binding. The binding incubations were conducted in a final volume of 0.5 ml TE buffer at 25° C. and were terminated after 30 minutes. Thioperamide (30 μM) was used to define non-specific binding. All binding reactions were terminated by filtration under vacuum onto polyethylenimine (0.3%) presoaked PERKINELMER UniFilter plates (PERKINELMER is a registered trademark of PerkinElmer, Inc. of Wellesley, Mass.) or WHATMAN GF/B filters (WHATMAN is a registered trademark of Whatman Paper Limited Company of the United Kingdom), followed by three brief washes with 2 ml of ice-cold TE buffer. Bound radiolabel was determined by liquid scintillation counting. For all of the radioligand competition binding assays, IC50 values and Hill slopes were determined by Hill transformation of the data and pKi values were determined by the Cheng-Prusoff equation.
- As shown in Table 1, the high Ki values obtained for the compounds of formula (I)) indicate that these compounds do not bind potently to histamine-3 receptors.
-
TABLE 1 Z1 Compound name Ki (nM)* CH (3aR,5R,6aR)-5-methyl-1-(4′-(6-oxopyridazin-1(6H)- >5000 yl)biphenyl-4-yl)octahydropyrrolo[3,4-b]pyrrole 5-oxide CH (3aR,5S,6aR)-5-methyl-1-(4′-(6-oxopyridazin-1(6H)- 2240 yl)biphenyl-4-yl)octahydropyrrolo[3,4-b]pyrrole 5-oxide *Values represent mean of 4 separate determinations. - The compounds of formula (I) are converted, after oral administration or in vivo administration to the compounds of formula (II). Compounds of formula (II) were tested as indicated above for histamine-3 receptor competition binding. As shown in Table 2, compounds of formula (II) have low Ki values. This indicates that compounds of formula (II) are extremely potent as histamine-3 receptors.
-
TABLE 2 Z2 Compound name Ki (nM) CH 2-(4′-((3aR,6aR)-5-methylhexahydropyrrolo[3,4-b]pyrrol- 8.2 1(2H)-yl)biphenyl-4-yl)pyridazin-3(2H)-one N 2-(5-(4-((3aR,6aR)-5-methylhexahydropyrrolo[3,4-b]pyrrol- 3.5 1(2H)-yl)phenyl)pyridin-2-yl)pyridazin-3(2H)-one - In addition to the utility of in vitro methods for characterizing the histamine-3 binding affinity of compounds, there are animal models of human disease available which demonstrate the utility of compounds of the invention for treating human diseases, conditions or disorders. One animal model of the human disease attention-deficit hyperactivity disorder and related human disorders of attention is an inhibitory avoidance test in SHR rat pups (a Spontaneously Hypertensive strain of rat pups). This model has also been alternatively termed a PAR (passive avoidance response) model. The methodology and utility of this test has been described in the literature, for example in Komater et al., Psychopharmacology (Berlin, Germany), Vol. 167(4), pp. 363-372 (2003); Fox et al., “Two Novel and Selective Nonimidazole H3 Receptor Antagonists A-304121 and A-317920: IL In vivo Behavioral and Neurophysiologies Characterization,” Journal of Pharmacology and Experimental Therapeutics, Vol. 305(3), pp. 897-908 (2003); Cowart et al., J. Med. Chem., Vol. 48, pp. 38-55 (2005); Fox et al., “Pharmacological Properties of ABT-239: IL Neurophysiological Characterization and Broad Preclinical Efficacy in Cognition and Schizophrenia of a Potent and Selective Histamine H3 Receptor Antagonist”, Journal of Pharmacology and Experimental Therapeutics, Vol. 313, pp. 176-190 (2005); Fox et al., “Effects of Histamine H3 Receptor Ligands GT-2331 and Ciproxifan in a Repeated Acquisition Avoidance Response in the Spontaneously Hypertensive Rat Pup”, Behavioural Brain Research, Vol. 131 (1,2), pp. 151-161 (2002). In this model, both compounds of formula (II) were active and showed statistically significant beneficial effects after dosing at 0.01-0.03 mg/kg of body weight, when dosed alone by intraperitoneal injection, with behavioral efficacy achieved over a range of plasma concentrations. As prodrugs, compounds of formula (I), when dosed in vivo at 1 mg/kg, produced sustained plasma concentrations of compounds of formula (II) far exceeding levels needed for efficacy, and consequently the preferred doses for compounds of formula (II) range from 0.003-0.1 mg/kg.
- Compounds of formula (I) are converted in vivo into compounds of formula (II), therefore compounds of formula (I) can be considered to be prodrugs of compounds of formula (II). This is demonstrated by the following experiments. The pharmacokinetic behavior of a prodrug was evaluated in CD-1 mice, Sprague-Dawley rats, cynomolgus monkeys and beagle dogs.
- The prodrug was prepared as a solution in a vehicle of 20% EtOH: 30% propylene glycol in D5W (dextrose 5% in water) at concentrations ranging from 0.1-2 mg/ml. Groups of three rats, dogs or monkeys received a 1 mg/kg (0.5-1 ml/kg) intravenous or oral dose of the example prodrug; additional groups of 30 mice received a 1 mg/kg (10 ml/kg) intravenous or oral dose of the prodrug. The intravenous dose was administered in a jugular (rat), cephalic (dog) or saphenous (monkey) vein; the oral dose was administered by gavage. Serial blood samples were obtained from each animal 0.1 (IV only), 0.25, 0.5, 1, 1.5, 2, 4, 6, 9, 12, 15 (dog only) and 24 hours after dosing. Plasma was separated by centrifugation and stored frozen until analysis.
- The plasma concentrations of the administered prodrug and the corresponding histamine-3 receptor ligand were determined by HPLC-MS/MS. The compounds of interest were removed from the plasma using protein precipitation with acetonitrile. Following centrifugation, the supernatant was transferred to a clean container and evaporated to dryness with nitrogen. The prodrug and parent compound were separated from co-extracted contaminant using reverse phase HPLC, with MS/MS detection and quantitation. Spiked standards were analyzed simultaneously with the samples. The plasma drug concentration of each sample was calculated by least squares linear regression analysis (non-weighted) of the peak area ratio (prodrug or parent/internal standard) of the spiked plasma standards versus concentration.
- Peak plasma concentrations (Cmax) and the time to peak plasma concentration (Tmax) for both the administered prodrug and the parent drug were read directly from the plasma concentration data for each rat. The plasma concentration data were submitted to multi-exponential curve fitting using WINNONLIN Professional Version 4.0 software (WINNONLIN is a registered trademark of Pharsight Corporation of Palo Alto, Calif.). The characterized prodrug converted to a histamine-3 receptor ligand in all studies. The conversion from the prodrug was measured: complete conversion of the prodrug was observed in the monkey (no prodrug detected); about 50% conversion was noted in rat (prodrug: parent ratio ˜1:1) and ˜30% conversion in mouse (prodrug: parent ratio ˜2:1); conversion was observed in dog (prodrug: parent ratio ˜10:1), but less than in monkey, rat, and mouse.
- It is understood that the foregoing detailed description and accompanying examples are merely illustrative and are not to be taken as limitations upon the scope of the invention, which is defined solely by the appended claims and their equivalents. Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art. Such changes and modifications, including without limitation those relating to the chemical structures, substituents, derivatives, intermediates, syntheses, formulations, or methods, or any combination of such changes and modifications of use of the invention, may be made without departing from the spirit and scope thereof.
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/208,604 US8026240B2 (en) | 2007-09-11 | 2008-09-11 | Octahydro-pyrrolo[3,4-b]pyrrole N-oxides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97140207P | 2007-09-11 | 2007-09-11 | |
US12/208,604 US8026240B2 (en) | 2007-09-11 | 2008-09-11 | Octahydro-pyrrolo[3,4-b]pyrrole N-oxides |
Publications (2)
Publication Number | Publication Date |
---|---|
US20090105267A1 true US20090105267A1 (en) | 2009-04-23 |
US8026240B2 US8026240B2 (en) | 2011-09-27 |
Family
ID=40040127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/208,604 Expired - Fee Related US8026240B2 (en) | 2007-09-11 | 2008-09-11 | Octahydro-pyrrolo[3,4-b]pyrrole N-oxides |
Country Status (8)
Country | Link |
---|---|
US (1) | US8026240B2 (en) |
EP (1) | EP2188288A1 (en) |
JP (1) | JP5665540B2 (en) |
CN (1) | CN101809021B (en) |
CA (1) | CA2691782A1 (en) |
MX (1) | MX2009013958A (en) |
RU (1) | RU2486187C2 (en) |
WO (1) | WO2009036132A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100222358A1 (en) * | 2006-02-24 | 2010-09-02 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole derivatives |
US9434695B2 (en) | 2012-07-18 | 2016-09-06 | Sunshine Lake Pharma Co., Ltd | Nitrogenous heterocyclic derivatives and their application in drugs |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
US9745308B2 (en) * | 2014-09-12 | 2017-08-29 | Chiesi Farmaceutici S.P.A. | Pyridazinone derivatives as phoshoinositide 3-kinases inhibitors |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5071999A (en) * | 1989-04-17 | 1991-12-10 | Bayer Aktiengesellschaft | Preparation of 2,7-diazabicyclo[3.3.0]octanes |
US20040092521A1 (en) * | 2002-11-12 | 2004-05-13 | Altenbach Robert J. | Bicyclic-substituted amines as histamine-3 receptor ligands |
US20050101602A1 (en) * | 2003-09-19 | 2005-05-12 | Anwer Basha | Substituted diazabicycloalkane derivatives |
US20050245543A1 (en) * | 2004-04-30 | 2005-11-03 | Pfizer Inc | Histamine-3 receptor antagonists |
US20060019998A1 (en) * | 2004-07-21 | 2006-01-26 | Pfizer Inc | Histamine-3 receptor antagonist |
US20080221093A1 (en) * | 2007-03-07 | 2008-09-11 | Christian Gege | Metalloprotease inhibitors containing a heterocyclic moiety |
US7462599B2 (en) * | 2003-10-15 | 2008-12-09 | Probiodrug Ag | Use of effectors of glutaminyl and glutamate cyclases |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CS229067B1 (en) | 1981-08-20 | 1984-04-16 | Svorad Stolc | Medicinal preparation with antiarhythmic and supporting effect applied with hypoxia,and method of preparing active substance thereof |
DE3906365A1 (en) | 1988-07-15 | 1990-01-18 | Bayer Ag | 7- (1-PYRROLIDINYL) -3-CHINOLONE AND NAPHTHYRIDONE CARBOXYLIC ACID DERIVATIVES, METHOD AND SUBSTITUTED (OXA) DIAZABICYCLOOCTANES AND NONANESE AS INTERMEDIATE PRODUCTS, AND ANTIBACTERIAL AGENTS AND FOOD ADDITIVES CONTAINING THEM |
ES2162047T3 (en) | 1995-05-11 | 2001-12-16 | Upjohn Co | OXAZOLIDINONES WITH REST DIAZINYL AND CARBAZINYL SPIROCICLICAL AND BICYCLE. |
CZ300570B6 (en) | 1998-10-27 | 2009-06-17 | Abbott Laboratories | Inhibitors of biosynthesis prostaglandin endoperoxide H synthase |
WO2001066534A2 (en) | 2000-03-09 | 2001-09-13 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
MY137020A (en) | 2000-04-27 | 2008-12-31 | Abbott Lab | Diazabicyclic central nervous system active agents |
ATE372981T1 (en) | 2000-07-13 | 2007-09-15 | Abbott Lab | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS LIGANDS OF THE HISTAMINE-3 RECEPTOR AND THEIR THERAPEUTIC APPLICATIONS |
RU2292345C9 (en) | 2000-07-17 | 2007-05-10 | Ранбакси Лабораторис Лимитед | Oxazolidinone derivatives |
US6316475B1 (en) | 2000-11-17 | 2001-11-13 | Abbott Laboratories | Aminoalkoxybiphenylcarboxamides as histamine-3 receptor ligands and their therapeutic applications |
US6906081B2 (en) | 2001-02-08 | 2005-06-14 | Schering Corporation | Use of dual H3/M2 antagonists in the treatment of cognition deficit disorders |
EP1368354A1 (en) | 2001-03-07 | 2003-12-10 | Pfizer Products Inc. | Modulators of chemokine receptor activity |
BR0309348A (en) * | 2002-04-18 | 2005-03-01 | Schering Corp | (1-4-Piperidinyl) benzimidazole derivatives useful as histamine h3 antagonists |
AU2003276930A1 (en) | 2003-03-24 | 2004-11-23 | Novascreen Biosciences Corporation | Drug discovery method and apparatus |
US7834014B2 (en) | 2003-04-09 | 2010-11-16 | Biogen Idec Ma Inc. | A2a adenosine receptor antagonists |
US20070225505A1 (en) | 2003-11-25 | 2007-09-27 | Pau Cid | Method for the Preparation of (2S, 3AR, 7AS)-Octahydro-III-Indole-2-Carboxylic Acid as Key Intermediate in the Preparation of Trandolapril by Reacting a Cyclohexyl Aziridine with a Dialkyl Malonate |
AU2004296531A1 (en) | 2003-12-15 | 2005-06-23 | H. Lundbeck A/S | The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist |
ATE437880T1 (en) | 2004-02-04 | 2009-08-15 | Neurosearch As | DIMERE AZACYCLIC COMPOUNDS AND THEIR USE |
US7435831B2 (en) | 2004-03-03 | 2008-10-14 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
DE102004039789A1 (en) | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Aryl-substituted polycyclic amines, process for their preparation and their use as pharmaceuticals |
GB0514018D0 (en) | 2005-07-07 | 2005-08-17 | Ionix Pharmaceuticals Ltd | Chemical compounds |
TW200800908A (en) | 2006-02-15 | 2008-01-01 | Sanofi Aventis | Novel azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments |
KR20080095879A (en) | 2006-02-15 | 2008-10-29 | 사노피-아벤티스 | Novel azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments |
US7728031B2 (en) | 2006-02-24 | 2010-06-01 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole derivatives |
EP2010505B1 (en) | 2006-03-28 | 2012-12-05 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
EP2035372A1 (en) | 2006-06-29 | 2009-03-18 | Arena Pharmaceuticals, Inc. | Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto |
WO2008014240A2 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
WO2008023239A1 (en) | 2006-08-23 | 2008-02-28 | Pfizer Products Inc. | Pyrimidone compounds as gsk-3 inhibitors |
WO2008024978A2 (en) | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Tetrahydroindolone and tetrahydroindazolone derivatives |
WO2008041090A1 (en) | 2006-10-06 | 2008-04-10 | Pfizer Limited | Malanin concentrating hormone receptor-1 antagonist pyridinones |
WO2008059238A1 (en) | 2006-11-17 | 2008-05-22 | Astrazeneca Ab | Benzenesulfonamide compounds as edg-1 antagonists useful in the treatment of cancer |
US20100292288A1 (en) | 2007-06-08 | 2010-11-18 | Arena Pharmaceuticals, Inc. | Crystalline forms of (r)-1-{2-[4`- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto |
-
2008
- 2008-09-11 JP JP2010524256A patent/JP5665540B2/en not_active Expired - Fee Related
- 2008-09-11 MX MX2009013958A patent/MX2009013958A/en active IP Right Grant
- 2008-09-11 CA CA002691782A patent/CA2691782A1/en not_active Abandoned
- 2008-09-11 US US12/208,604 patent/US8026240B2/en not_active Expired - Fee Related
- 2008-09-11 RU RU2010114206/04A patent/RU2486187C2/en not_active IP Right Cessation
- 2008-09-11 EP EP08830602A patent/EP2188288A1/en not_active Withdrawn
- 2008-09-11 CN CN2008800231456A patent/CN101809021B/en not_active Expired - Fee Related
- 2008-09-11 WO PCT/US2008/075967 patent/WO2009036132A1/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5071999A (en) * | 1989-04-17 | 1991-12-10 | Bayer Aktiengesellschaft | Preparation of 2,7-diazabicyclo[3.3.0]octanes |
US20040092521A1 (en) * | 2002-11-12 | 2004-05-13 | Altenbach Robert J. | Bicyclic-substituted amines as histamine-3 receptor ligands |
US20050101602A1 (en) * | 2003-09-19 | 2005-05-12 | Anwer Basha | Substituted diazabicycloalkane derivatives |
US7462599B2 (en) * | 2003-10-15 | 2008-12-09 | Probiodrug Ag | Use of effectors of glutaminyl and glutamate cyclases |
US20050245543A1 (en) * | 2004-04-30 | 2005-11-03 | Pfizer Inc | Histamine-3 receptor antagonists |
US20060019998A1 (en) * | 2004-07-21 | 2006-01-26 | Pfizer Inc | Histamine-3 receptor antagonist |
US20080221093A1 (en) * | 2007-03-07 | 2008-09-11 | Christian Gege | Metalloprotease inhibitors containing a heterocyclic moiety |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100222358A1 (en) * | 2006-02-24 | 2010-09-02 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole derivatives |
US8399468B2 (en) | 2006-02-24 | 2013-03-19 | Abbott Laboratories | Octahydro-pyrrolo[3,4-B]pyrrole derivatives |
US9434695B2 (en) | 2012-07-18 | 2016-09-06 | Sunshine Lake Pharma Co., Ltd | Nitrogenous heterocyclic derivatives and their application in drugs |
Also Published As
Publication number | Publication date |
---|---|
WO2009036132A1 (en) | 2009-03-19 |
US8026240B2 (en) | 2011-09-27 |
EP2188288A1 (en) | 2010-05-26 |
CA2691782A1 (en) | 2009-03-19 |
RU2486187C2 (en) | 2013-06-27 |
RU2010114206A (en) | 2011-10-20 |
MX2009013958A (en) | 2010-03-10 |
CN101809021B (en) | 2013-04-24 |
JP5665540B2 (en) | 2015-02-04 |
JP2010539099A (en) | 2010-12-16 |
CN101809021A (en) | 2010-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8399468B2 (en) | Octahydro-pyrrolo[3,4-B]pyrrole derivatives | |
DE60318030T2 (en) | PIPERAZINE-SUBSTITUTED ARYL-BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOSES | |
CA2566898C (en) | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands | |
JP5649975B2 (en) | Cyclopropylamine derivative | |
JP5203360B2 (en) | Cyclopropylamine derivatives as histamine H3 receptor modulators | |
WO2009137503A1 (en) | Hdac inhibitors and uses thereof | |
IE58237B1 (en) | Condensed diazepinones, processes for preparing them and pharmaceutical compositions containing these compounds | |
US8026240B2 (en) | Octahydro-pyrrolo[3,4-b]pyrrole N-oxides | |
JP2009508957A (en) | Benzothiazole cyclobutylamine derivatives and their use as histamine-3 receptor ligands | |
DE602004004550T2 (en) | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND APPLICATION METHODS | |
AU2013216616B2 (en) | Cyclopropyl amine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ABBOTT LABORATORIES, ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COWART, MARLON D.;MARSH, KENNAN C.;LIU, HUAQING;AND OTHERS;REEL/FRAME:022057/0727;SIGNING DATES FROM 20081208 TO 20081218 Owner name: ABBOTT LABORATORIES, ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COWART, MARLON D.;MARSH, KENNAN C.;LIU, HUAQING;AND OTHERS;SIGNING DATES FROM 20081208 TO 20081218;REEL/FRAME:022057/0727 |
|
ZAAA | Notice of allowance and fees due |
Free format text: ORIGINAL CODE: NOA |
|
ZAAB | Notice of allowance mailed |
Free format text: ORIGINAL CODE: MN/=. |
|
ZAAA | Notice of allowance and fees due |
Free format text: ORIGINAL CODE: NOA |
|
ZAAB | Notice of allowance mailed |
Free format text: ORIGINAL CODE: MN/=. |
|
ZAAA | Notice of allowance and fees due |
Free format text: ORIGINAL CODE: NOA |
|
ZAAB | Notice of allowance mailed |
Free format text: ORIGINAL CODE: MN/=. |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: ABBVIE INC., ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ABBOTT LABORATORIES;REEL/FRAME:030237/0588 Effective date: 20120801 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
AS | Assignment |
Owner name: ABBOTT LABORATORIES, ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ZHAO, CHEN;REEL/FRAME:036323/0483 Effective date: 20150610 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20230927 |